Document:

EX-10.23

 Exhibit 10.23 

LICENSE AGREEMENT 

between 
 PRESIDENT AND
FELLOWS OF HARVARD COLLEGE 
 and 

RAINDANCE TECHNOLOGIES, INC. 

Dated: February 23, 2006 
  

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE
COMMISSION. 

 Table of Contents 

 

							
	 Section
	  	 	  	Page	 
	1	  	Definitions	  	 	1	  
			
	2	  	Title	  	 	7	  
			
	3	  	Patent Filing, Prosecution and Maintenance	  	 	7	  
			
	4	  	License Grant	  	 	9	  
			
	5	  	Developments and Commercialization	  	 	13	  
			
	6	  	Consideration for Grant of License	  	 	14	  
			
	7	  	Reports; Payments; Records	  	 	17	  
			
	8	  	Enforcement of Patent Rights	  	 	19	  
			
	9	  	Warranties; Limitation of Liability	  	 	21	  
			
	10	  	Indemnification	  	 	22	  
			
	11	  	Terms and Termination	  	 	24	  
			
	12	  	Miscellaneous	  	 	25	  

  

							
			
	 Exhibit 1.3
	  	 	—  	  	  	Development Milestones
			
	 Exhibit 1.4
	  	 	—  	  	  	Development Plan
			
	 Exhibit 1.5
	  	 	—  	  	  	Exclusive Harvard Patent Rights
			
	 Exhibit 1.7
	  	 	—  	  	  	Harvard Case [****] Patent Rights
			
	 Exhibit 1.8
	  	 	—  	  	  	Harvard Case [****] Patent Rights
			
	 Exhibit 1.9
	  	 	—  	  	  	Harvard Case [****] Patent Rights
			
	 Exhibit 1.10
	  	 	—  	  	  	Harvard [****] Patent Rights
			
	 Exhibit 1.17
	  	 	—  	  	  	Non-Exclusive Harvard Patent Rights
			
	 Exhibit 6.2.1.2
	  	 	—  	  	  	Raindance Capitalization Table

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 LICENSE AGREEMENT 

This License Agreement is entered into as of this 23rd day of February, 2006
(the “Effective Date”), by and between Raindance Technologies, Inc., a Delaware corporation, having a principle place of business at 530 Whitfield Street, Guilford CT 06437 (“Licensee”) and President and
Fellows of Harvard College, Holyoke Center, Suite 727, 1350 Massachusetts Ave., Cambridge, MA (“Harvard”). 

WHEREAS, Harvard is: (i) the owner of the Exclusive Harvard Patent Rights, Harvard Case [****] Patent Rights and the Non-Exclusive
Harvard Patent Rights (as such terms are defined below), (ii) a joint owner of the Case [****] Patent Rights (as such term is defined below), with sole authority to grant licenses under such patent rights in accordance [****]
(iii) joint owner of the Harvard [****] Patent Rights (as such term is defined below), with respect to which patent rights Harvard [****] and (iv) joint owner of the Case [****] Patent Rights (as such term is defined below), with
respect to which patent rights Harvard [****]; 
 WHEREAS, Harvard desires to have products based on the Licensed Patent Rights (as defined
below) developed and commercialized to benefit the public and is willing to grant a license under its rights in the Licensed Patent Rights; 

WHEREAS, Licensee has represented to Harvard, in order to induce Harvard to enter into this Agreement, that Licensee shall commit itself to
thorough, vigorous and diligent efforts to develop, obtain regulatory approval for (if needed) and commercialize products based on the Licensed Patent Rights; and 

WHEREAS, Licensee wishes to obtain a license under the Licensed Patents Rights and Harvard wishes to grant Licensee a license under its
interest in the Licensed Patent Rights, all in accordance with the terms and conditions of this Agreement. 
 NOW, THEREFORE, the parties hereto, intending
to be legally bound, hereby agree as follows: 
  

	1.	Definitions. 

 Whenever used in this Agreement with an initial capital letter, the terms
defined in this Section 1, whether used in the singular or the plural, shall have the meanings specified below. 
 1.1.
“Affiliate” shall mean, with respect to either party, any person, organization or entity controlling, controlled by or under common control with, such parry. For purposes of this definition only, “control” of another
person, organization or entity shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the activities, management or policies of such person, organization or entity, whether through the ownership of voting
securities, by contract or otherwise. Without limiting the foregoing, control shall be presumed to exist when a person, organization or entity (i) owns or directly controls twenty percent (20%) or more of the outstanding voting stock or
other ownership interest of the other organization or  

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 
entity, or (ii) possesses, directly or indirectly the power to elect or appoint twenty percent (20%) or more of the members of the governing body of the organization or other entity.

 1.2. “Calendar Quarter” [****], for so long as this Agreement is in effect. 

1.3 “Development Milestones” shall mean the development milestones set forth in Exhibit 1.3 hereto. 

1.4 “Development Plan” shall mean the plan for the development of Licensed Products attached hereto as
Exhibit 1.4, as such plan may be amended from time to time pursuant to Section 5.2. 
 1.5. “Exclusive
Harvard Patent Rights” shall mean, in each case to the extent owned and controlled by Harvard: (a) the patent applications and patents listed in Exhibit 1.5; (b) any patent or patent application that claims priority to and is a
divisional, continuation, reissue, renewal, reexamination, substitution or extension of at least one of the patents or patent applications identified in (a); (c) any patents issuing on any of the patent applications identified in (a) or
(b); (d) any claim of a continuation-in-part application or patent, which claim is entitled to the priority date of, and is directed at subject matter described in, at least one of the patents or patent applications identified in (a),
(b) or (c); and (e) any foreign counter-part of any of the patents or patent applications identified in (a), (b) or (c) or of the claims identified in (d). 

1.6. “Field” shall mean: 

1.6.1. [****] 

1.6.2. [****] and 

1.6.3. [****]. 

1.7. “Harvard Case [****] Patent Rights” shall mean, in each case to the extent owned and controlled by
Harvard, Harvard’s interest in: (a) the patent applications and patents listed in Exhibit 1.7; (b) any patent or patent application that claims priority to and is a divisional, continuation, reissue, renewal, reexamination,
substitution or extension of at least one of the patents or patent applications identified in (a); (c) any patents issuing on any of the patent applications identified in (a) or (b); (d) any claim of a continuation-in-part application
or patent, which claim is entitled to the priority date of, and is directed at subject matter described in, at least one of the patents or patent applications identified in (a), (b) or (c); and (e) any foreign counter-part of any of the
patents or patent applications identified in (a), (b) or (c) or of the claims identified in (d). 
 1.8.
“Harvard Case [****] Patent Rights” shall mean, in each case to the extent owned (or co-owned) and controlled by Harvard: (a) the patent applications and patents listed in Exhibit 1.8; (b) any patent or patent
application that claims priority to and is a divisional, continuation, reissue, renewal, reexamination, substitution or extension of at least one of the patents or patent applications identified in (a); (c) any patents issuing on any of the
patent  

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 
applications identified in (a) or (b); (d) any claim of a continuation-m-part application or patent, which claim is entitled to the priority date of, and is directed at subject matter
described in, at least one of the patents or patent applications identified in (a), (b) or (c); and (e) any foreign counter-part of any of the patents or patent applications identified in (a), (b) or (c) or of the claims
identified in (d). 
 1.9. “Harvard Case [****] Patent Rights” shall mean, in each case to the extent owned
and controlled by Harvard: (a) the patent applications and patents listed in Exhibit 1.9; (b) any patent or patent application that claims priority to and is a divisional, continuation, reissue, renewal, reexamination, substitution or
extension of at least one of the patents or patent applications identified in (a); (c) any patents issuing on any of the patent applications identified in (a) or (b); (d) any claim of a continuation-in-part application or patent,
which claim is entitled to the priority date of, and is directed at subject matter described in, at least one of the patents or patent applications identified in (a), (b) or (c); and (e) any foreign counter-part of any of the patents or
patent applications identified in (a), (d) or (c) or of the claims identified in (d). 
 1.10. “Harvard
[****] Patent Rights” shall mean, in each case to the extent owned and controlled by Harvard, Harvard’s interest in: (a) the patent applications and patents listed in Exhibit 1.10; (b) any patent or patent
application that claims priority to and is a divisional, continuation, reissue, renewal, reexamination, substitution or extension of at least one of the patents or patent applications identified in (a); (c) any patents issuing on any of the
patent applications identified in (a) or (b); (d) any claim of a continuation-in-part application or patent, which claim is entitled to the priority date of, and is directed at subject matter described in, at least one of the patents or
patent applications identified in (a), (b) or (c); and (e) any foreign counter-part of any of the patents or patent applications identified in (a), (b) or (c) or of the-claims identified in (d). 

1.11. “Licensed Patent Rights” shall mean Exclusive Harvard Patent Rights, the Non-Exclusive Harvard Patent Rights,
Harvard Case [****] Patent Rights, Harvard Case [****] Patent Rights, Harvard Case [****] Patent Rights and Harvard’s interest in the Harvard [****] Patent Rights. 

1.12. “Licensed Process” shall mean [****] which would constitute, but for the grant of a license under Licensed
Patent Rights within the Field, an infringement of a Valid Claim in the country in which such method is used or in the country in which the resulting products are sold. 

1.13. “Licensed Product” shall mean any product that meets one of the following definitions: 

1.13.1. “Type A Product” shall mean [****]. 

1.13.2. “Type B Product” any [****]. 

1.13.3. “Type C Product” shall mean [****]. 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 1.13.4. “Type D Product” shall mean [****]. 

1.14. [****]. 
 1.15. [****].

 1.16. “Net Sales” shall mean all amounts billed, invoiced, or received (whichever first occurs) by Licensee, its
Affiliates and/or any Sublicensee(s) for sales, leases, or other transfers of Licensed Product(s) (including, without limitation, all amounts billed, invoiced, or received (whichever first occurs) by Licensee, its affiliates and any Sublicensee(s)
for performance or other provision of, or agreement to perform or otherwise provide, any Service), less: 
 (a) customary trade,
quantity or cash discounts and non-affiliated brokers’ or agents’ commissions actually allowed and taken; 
 (b) refunds for goods
rejected or returned and charge backs and rebates actually taken by customers that effectively reduce net revenue; 
 (c) to the extent
separately stated on purchase orders, invoices or other documents of sale, taxes levied on- and/or other governmental charges made as to production, sale, transportation, delivery or use of such Licensed Products and paid by or on behalf of Licensee
or any Sublicensee(s); and 
 (d) reasonable charges for delivery or transportation provided by third parties, if separately stated and
actually paid by Licensee or any Sublicensee(s). 
 Net Sales also includes the fair market value of any non-cash consideration received by
Licensee, any of its Affiliates and any Sublicensee(s) for the sale, lease or transfer of Licensed Product(s). Fair market value will be calculated as of the time of transfer of such non-cash consideration to Licensee, such Affiliate(s) or such
Sublicensee(s). Transfer of a Licensed Product between Licensee and an Affiliate of Licensee or between Licensee and a Sublicensee for sale by the transferee shall not be considered Net Sales for purposes of ascertaining royalty charges, and Net
Sales shall be determined based on the sales by the transferee. 
 1.17. “Non-Exclusive Harvard Patent Rights” shall
mean, in each case to the extent owned and controlled by Harvard: (a) the patent applications and patents listed in Exhibit 1.17; (b) any patent or patent application that claims priority to and is a divisional, continuation, reissue,
renewal, reexamination, substitution or extension of at least one of the patents or patent applications identified in (a); (c) any patents issuing on any of the patents or patent applications identifies in (a) or (b); (d) any claim of
a continuation-in-part application or patent, which claim is entitled to the priority date of, and is directed at subject matter described in, at least one of the patents or patent applications identified in (a), (b) or (c); and (e) any
foreign counter-part of any of the patents or patent applications identified in (a), (b) or (c) or of the claims identified in (d). 

1.18. “Non-Royalty Sublicense Income” shall mean Sublicense issue fees, Sublicense maintenance fees, Sublicense
milestone payments, and any other amounts, except for royalties  

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 
on Net Sales, received by Licensee or any of its Affiliates on account of or in connection with Sublicense(s) (or an option to grant a Sublicense), excluding bona fide: (a) [****].
Non-Royalty Sublicense Income also includes the fair market value of any non-monetary consideration received by Licensee or any of its Affiliates in connection with a Sublicense, excluding royalties on Net Sales. 

1.19. “Service” shall mean [****]. 

1.20. “Sublicense” shall mean a grant by Licensee to a third party of a sublicense or other grant of right to
exercise, or have exercised by such party, some or all of the rights granted to Licensee in accordance with the terms of this Agreement (regardless of whether such gram; of rights is referred to or is described as a sublicense). 

1.21. “Sublicensee” shall mean any person or entity granted a Sublicense. 

1.22. “Third Party License” shall mean a license obtained by Licensee from an unaffiliated third party to one or more
valid and enforceable patents issued in the United States or any other jurisdiction, the claims of which cover one or more functional components that is essential for the efficacy of the Licensed Product, which Licensee is legally required to obtain
in order to make, use or sell such Licensed Product in the country in which such Licensed Product is made, used or sold. 
 1.23.
[****]. 
 1.24. “Valid Claim” shall mean (a) a pending claim of a patent application within the Licensed
Patent Rights, which (i) has been asserted in good faith, and (ii) has not been abandoned or finally rejected without the possibility of appeal or refiling; or (b) a claim of an issued or granted and unexpired patent within the
Licensed Patent Rights, which has not been held unenforceable, unpatentable or invalid by a decision of a court or governmental body of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, which has not been
rendered unenforceable through disclaimer or otherwise, which has not been abandoned, and which has not been lost through an interference proceeding. 

1.25. “[****] Licensed Product” shall mean [****]. 
  

	2.	Title. 

 Subject to the licenses granted to Licensee pursuant to Section 4 below,
all rights, title and interest in and to (a) the Exclusive Harvard Patent Rights, the Non-Exclusive Patent Rights, the Harvard Case [****] Patent Rights and the Harvard Case [****] Patent Rights and Harvard’s interest in the
Harvard [****] Patent Rights are and shall be owned solely and exclusively by Harvard (b) the Harvard Case [****] Patent Rights are and shall be owned solely and exclusively by Harvard [****]. 

 

	3.	Patent Filing, Prosecution and Maintenance. 

 3.1. Responsibility. [****]. 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 3.2. Consultation with respect to Harvard Exclusive Patent Rights. [****]. 

3.3. Expenses. 

3.3.1. Exclusively Licensed Patent Rights. [****]. 

3.3.2. Other Harvard Patent Rights. [****]. 

3.4. Abandonment. [****]. 

3.5. No Warranty. Nothing contained herein shall be deemed to be a warranty by Harvard that it can or will be able to obtain
patents on patent applications included in the Licensed Patent Rights, or that any of the Licensed Patent Rights will afford adequate or commercially worthwhile protection. 

3.6. Small Entity Designation. If Licensee, any Sublicensee and/or any holder of an option to obtain a Sublicense does not
qualify, or at any point during the term of this Agreement ceases to qualify, as a “small entity” as provided by the United States Patent and Trademark Office (USPTO), Licensee shall so notify Harvard immediately, in order to enable
Harvard to .comply with USPTO regulations regarding payment of fees with respect to Licensed Patent Rights. 
  

	4.	License Grant. 

 4.1. Licenses. 

4.1.1. Exclusive Licenses. 

4.1.1.1. Exclusive Harvard Patent Rights. Subject to the terms and conditions set forth in this Agreement, Harvard
hereby grants to Licensee an exclusive (except as set forth in Section 4.1.1.4 below), worldwide, royalty-bearing license under the Exclusive Harvard Patent Rights solely to [****]. 

4.1.1.2. Harvard [****] Patent Rights. Subject to the terms and conditions set forth in this Agreement, Harvard
hereby grants to Licensee an exclusive (except as set forth in Section 4.1.1.4 below), royalty-bearing license under Harvard’s interest in the Harvard [****]Patent Rights solely to [****]. 

4.1.1.3. Harvard Case [****] Patent Rights. Subject to the terms and conditions set forth in this Agreement,
Harvard hereby grants to Licensee an exclusive (except as set forth in Section 4.1.1.3 below), worldwide, royalty-bearing license under the Harvard Case [****] Patent Rights solely to [****]. 

4.1.1.4. Limitations on Exclusivity. The licenses granted under Sections 4.1.1.1, 4.1.1.2 and 4.1.1.3 are subject to
the following limitations: 
 (a) [****]. 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 (b) U.S. Government Rights. The U.S. federal government retains rights in the
Licensed Patent Rights pursuant to 35 USC §§ 200-212, 37 CFR § 401 et seq. and applicable governmental implementing regulations, and any right granted in this Agreement greater than that permitted under
35 USC §§ 200-212 or 37 CFR § 401 et seq. shall be subject to modification as may be required to conform to the provisions of those statutes. 

(c) [****]. 
  

	 	(i)	[****]. 

  

	 	(ii)	[****]. 

  

	 	(iii)	[****]. 

  

	 	(iv)	[****]. 

  

	 	(v)	[****]. 

 4.1.2. Non-Exclusive Licenses. 

4.1.2.1. Non-Exclusive Harvard Patent Rights. Subject to the terms and conditions set forth in this Agreement, Harvard hereby
grants to Licensee a non-exclusive, worldwide, royalty-bearing license under the Non-Exclusive Harvard Patent Rights solely to [****]. 

4.1.2.2. Harvard Case [****] Patent Rights. Subject to the terms and conditions set forth in this Agreement,’ Harvard
hereby grants to Licensee a non-exclusive, royalty-bearing license under the Harvard Case [****] Patent Rights solely to [****]. 
 4.2
Sublicense. 
 4.2.1. Sublicense Grant. Licensee shall be entitled to grant Sublicenses to third parties under the
license granted pursuant to Section 4.1 on terms and conditions in compliance with and not inconsistent with the terms of this Agreement. Such Sublicenses shall only be made’ for consideration and in bona-fide arm’s length
transactions. 
 4.2.2. Sublicense Agreements. Sublicenses shall only be granted pursuant to written agreements, which shall
be subject and subordinate to the terms and conditions of this Agreement. Such, sublicense agreements shall contain, among other things, provisions to the following effect: 

4.2.2.1. All provisions necessary to ensure Licensee’s ability to perform its obligations under this Agreement, including
without limitation its obligations under Sections 5, 7.1, 7.3, 7.4 and 12.1; 
 4.2.2.2. [****]. 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 4.2.2.3. [****]. 

4.2.2.4. [****]. 

4.2.2.5. [****]. 

4.2.3. Delivery of Sublicense Agreement. Licensee shall furnish Harvard with a fully executed copy of any such
Sublicense agreement, promptly after its execution. Harvard shall keep any such copies of Sublicense agreements in its confidential files and shall use them solely for the purpose of monitoring Licensee’s and Sublicensees’ compliance with
their obligations hereunder and enforcing Harvard’s rights under this Agreement. 
 4.2.4. Breach by
Sublicensee. Any act or omission by a Sublicensee, which would have constituted a breach of this Agreement had it been an act or omission by Licensee, shall constitute a breach of this Agreement. [****]. 

4.3. No Other Grant of Rights. Nothing in this Agreement shall be construed to confer any rights upon Licensee by implication,
estoppel, or otherwise as to any technology or patent rights of Harvard or any other entity other than the Licensed Patent Rights, regardless of whether such technology or patent rights shall be dominant, subordinate or otherwise related to any
Licensed Patent Rights. 
  

	5.	Development and Commercialization. 

 5.1. Diligence. Licensee shall use
its best efforts, and/or shall cause its Affiliates or Sublicensees to use their best efforts: (i) to develop Licensed Products in accordance with the Development Plan, (ii) to introduce Licensed Products into the commercial market and
(iii) to market Licensed Products following such introduction into the market. In addition, Licensee, by itself or through Affiliates or Sublicensees, shall meet each of the Development Milestones within the time periods set forth therein.

 5.2. Development Plan. Licensee shall be entitled, from time to time, to make such adjustments to the then applicable
Development Plan as Licensee believes, in its good faith judgment, are needed in order to improve Licensee’s ability to meet the Development Milestones. 

5.3. Reporting. Within sixty (60) days after the end of each calendar year, Licensee shall furnish Harvard with a written
report on the progress of its, its Affiliates’ and Sublicensees’ efforts during the prior year to develop and commercialize Licensed Products, including without limitation research and development efforts and marketing efforts. The report
shall also contain a discussion of intended efforts for the then current year. 
 5.4. Failure. If Licensee breaches
any of its obligations under Section 5.1, Harvard shall notify Licensee in writing of Licensee’s failure and shall allow Licensee ninety (90) days to cure or to demonstrate that it has begun to cure its failure. Licensee’s
failure to cure or demonstrate that it has begun to cure such delay to Harvard’s reasonable satisfaction within such  

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 
90-day period shall constitute a material breach of this Agreement and Harvard shall have the right to terminate this Agreement forthwith. 

 

	6.	Consideration for Grant of License. 

 6.1. License Fee. In partial
consideration for the licenses granted to Licensee pursuant to Section 4 above, Licensee shall pay Harvard a non-refundable license issuance fee of [****] within thirty (30) business days after the Effective Date. 

6.2. Shares. 

6.2.1. Issuance. 

6.2.1.1 As partial consideration for the licenses granted hereunder, within thirty (30) days of the execution of this
Agreement, Licensee shall issue Harvard [****] shares of Licensee Common Stock (constituting approximately [****] of the outstanding capital stock of Licensee as of the Effective Date, on a fully-diluted basis) (the “Shares”). 

6.2.1.2. Licensee hereby represents as follows: 

(a) The capitalization table attached hereto as Exhibit 6.2.1.2 (the “Cap Table”) sets forth all of the
outstanding capital stock of Licensee on a fully-diluted basis as of the Effective Date. 
 (b) Other than as set forth in
the Cap Table, as of the Effective Date, there are no outstanding shares of capital stock, convertible securities, outstanding warrants, options or other rights to subscribe for, purchase or acquire from Licensee any capital stock of Licensee and
there are no contracts or binding commitments providing for the issuance of, or the granting of rights to acquire, any capital stock of Licensee or under which Licensee is, or may become, obligated to issue any of its securities; and 

(c) The Shares, when issued pursuant to the terms hereof, shall, upon such issuance, be duly authorized, validly issued,
fully paid and nonassessable. 
 6.2.2. [****]. 

6.2.2.1. [****]. 

6.2.2.2. [****]. 

6.2.2.3. For purposes of this Section 6.2.2: 

(a) [****] 

(b) [****]. 

(c) [****]. 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 6.3. Maintenance Fee. Upon [****] and on each anniversary of the date of [****],
Licensee shall pay to Harvard a license maintenance fee in the amount [****]. Each payment made under this Section 6.2 shall be creditable against amounts paid under Section 6.4 below for sales of Licensed Products made in the same
calendar year of such payment. 
 6.4. Net Sales. 

6.4.1. Licensee shall pay Harvard the following royalties on Net Sales: 

(a) An amount equal to [****] of all Net Sales of Type A Products; 

(b) An amount equal to [****] of all Net Sales of Type B Products; 

(c) An amount equal to [****] of all Net Sales of Type C Products; and 

(d) An amount equal to [****] of all Net Sales of Type D Products. 

6.4.2. [****]. 

6.4.3. Notwithstanding the foregoing, in the event that Licensee or an Affiliate of Licensee is required to make royalty payments, at
fair market terms after arms’ length negotiations, under a Third Party License as a result of the sale of a Licensed Product in a certain country, Licensee may .offset such Third-party payments with respect to such sale of such Licensed Product
against the royalty payments that are due to Harvard pursuant to Section 6.4.1 with respect to sales of such Licensed Product in such country; provided, however, that in no event, shall the royalty payments to Harvard under
Section 6.4.1 with respect to such Licensed Product be reduced by more than [****] of the amount otherwise due with respect to such Licensed Product. 

6.5. Non-Royalty Income. 

6.5.1. In addition, Licensee shall pay Harvard an amount equal to [****] of all Non-Royalty Sublicense Income. 

6.5.2. Notwithstanding Section 6.5.1: 

(a) [****]. 

(b) if a Sublicense includes a grant of rights under patents in-licensed by Licensee from an unaffiliated third party other
than [****], at fair market terms after arms’ length negotiations, and such patents- are necessary for the manufacture, sale or use of any licensed Products for which the Sublicense is being granted, Licensee shall be entitled to deduct from
the royalties which would otherwise be due to Harvard under Sections 6.5.1 or [****] (as applicable) the amount of royalties which Licensee must pay to such third parties on account of such Sublicense; provided, however, that in no event shall the
royalty due to Harvard be reduced !by more than [****] of the amounts set forth in Section 6.5.1 or [****] (as applicable). 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

	7.	Reports; Payments; Records. 

 7.1. Reports and Payments. 

7.1.1 Reports. Within [****] after the conclusion of each Calendar quarter commencing with the first Calendar Quarter in which
Net Sales are generated, Licensee shall deliver to Harvard a report containing the following information: 
 [****] 

If no amounts are due to Harvard for any Calendar Quarter, the report shall so state. 

7.1.2. Payment for Net Sales. Within [****] of end of each Calendar Quarter, Licensee shall pay Harvard all amounts due with
respect to Net Sales for the applicable Calendar Quarter. 
 7.1.3. Payment for Non-Royalty Sublicense Income. In addition
to the reports delivered pursuant to Section 7.1.1, Licensee shall notify Harvard in writing within [****] of the receipt of any Non-Royalty Sublicense Income. Licensee shall pay Harvard all amounts due with respect to such Non-Royalty
Sublicense Income within [****] of the receipt of such Non-Royalty Sublicense Income by Licensee or its Affiliates. 
 7.2.
Payment Currency. All payments due under this Agreement shall be payable in United States dollars. Conversion of foreign currency to U.S. dollars shall be made at the conversion rate existing in the United States (as reported in
The Wall Street Journal) on the last working day of the applicable Calendar Quarter. Such payments shall be without deduction of exchange, collection, or other charges. 

7.3. Records. Licensee shall maintain, and shall cause its Affiliates and Sublicensees to maintain, complete and accurate
records of Licensed Products that are made, used or sold under this Agreement, any amounts payable to Harvard in relation to such Licensed Products and all Non-Royalty Sublicense Income received by Licensee and its Affiliates, which records shall
contain sufficient information to permit Harvard to confirm the accuracy of any reports or notifications delivered to Harvard under Section 7.1. The relevant party shall retain such records relating to a given Calendar Quarter for at least
three (3) years after the conclusion of that Calendar Quarter, during which time Harvard shall have the right, at its expense, to cause an independent, certified public accountant to inspect such records during normal business hours for the
sole purpose of verifying any reports and payments delivered under this Agreement. Such accountant shall not disclose to Harvard any information other than information relating to. the accuracy of reports and payments delivered under this Agreement.
The parties shall reconcile any underpayment or overpayment within thirty (30) days after the accountant delivers the results of the audit. In the event that any audit performed under this Section 7.3 reveals an underpayment in excess of
[****] in any calendar year, the audited party shall bear the full cost of such audit. Harvard may exercise its rights under this Section 7.3 only once every year per audited party and only with reasonable prior notice to the audited party.

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 7.4. Audited Report. Licensee shall furnish Harvard, and shall cause its Affiliates
and Sublicensees to furnish Harvard, within ninety (90) days after the end of each calendar year, commencing at the end of the calendar year in which Net Sales are first generated or in which Non-Royalty Sublicense Income is first received,
with a report, certified by an independent certified public accountant, relating to royalties and other payments due to Harvard pursuant to this Agreement in respect to the previous calendar year and containing the same details as those specified in
Section 7.1 above in respect to the previous calendar year. 
 7.5. Late Payments. Any payments by Licensee that
are not paid on or before the date such payments are due under this Agreement shall bear interest at the lower of (a) [****] and (b) the maximum rate allowed by law. Interest shall accrue beginning on the first day following the due date
for payment and shall be compounded quarterly. Payment of such interest by Licensee shall not limit, in any way, Harvard’s right to exercise any other remedies Harvard may have as a consequence of the lateness of any payment. 

7.7. Payment Method. Each payment due to Harvard under this Agreement shall be paid by check or wire transfer of funds to
Harvard’s account in accordance with written instructions provided by Harvard. If made by wire transfer, such payments shall be marked so as to refer to this Agreement. 

7.8. Withholding and Similar Taxes. All amounts to be paid to Harvard pursuant to this Agreement shall be without deduction of
exchange, collection, or other charges, and, specifically, without deduction of withholding or similar taxes or other government imposed fees or taxes, except as permitted in the definition of Net Sales. 

 

	8.	Enforcement of Patent Rights. 

 8.1. Notice. In the event either party
becomes aware of any possible or actual infringement of any (a) Exclusive Harvard Patent Rights relating to Licensed Products [****], (b) Harvard [****] Patent Rights [****] relating to Licensed Product [****], or (c) Harvard
Case [****] Patent Rights relating to [****] Licensed Products [****], (each of the possible or actual infringements described in (a), (b) or (c) shall be referred to as an “Infringement”), that party shall promptly
notify the other party and provide it with details regarding such Infringement 
 8.2. [****]. 

8.3. [****]. 
 8.4. [****]. 

8.5. [****]. 
 8.6. [****]. 

8.7. [****]. 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

	9.	Warranties; Limitation of Liability. 

 9.1. Compliance with Law. Licensee
warrants that it will comply, and ensure that its Affiliates and Sublicensees comply, with, all local, state, and international laws and regulations relating to the development, manufacture, use, and sale of Licensed Products. Without limiting the
foregoing, Licensee represents and warrants that it shall, and shall ensure that its Affiliates and Sublicensees shall, comply with all United States export control laws and regulations with respect to Licensed Products. 

9.2. No Warranty. 

9.2.1. Harvard makes no warranties whatsoever as to the commercial or scientific value of the Licensed Patent Rights or the
inventions disclosed therein. Harvard makes no representation that the practice of the Licensed Patent Rights or the manufacture, use or sale of any Licensed Product, or any element thereof, will not infringe the patent or proprietary rights of any
third party. 
 9.2.2. Except as otherwise expressly provided in this Agreement, no party makes any warranty with respect to
any technology, patents, goods, services, rights or other subject matter of this Agreement and hereby disclaims warranties of merchantability, fitness for a particular purpose and noninfringement with respect to any and all of the foregoing. 

9.3. Limitation of Liability. 

9.3.1. Subject to Section 10, neither party will be liable to the other with respect to any subject matter of this
Agreement under any contract, negligence, strict liability or other legal or equitable theory for (i) any indirect, incidental, consequential or punitive damages or lost profits or (ii) cost of procurement of substitute goods, technology
or services. 
 9.3.2. [****]. 
  

	10.	Indemnification. 

 10.1. Indemnity. 

10.1.1. [****]. 

10.1.2. [****]. 

10.2. Insurance. 

10.2.1. Beginning at the time any such product, process or service is being commercially distributed or sold (other than for
the purpose of obtaining regulatory approvals) by Licensee, or by an Affiliate, Sublicensee or agent of Licensee, Licensee shall, at its sole cost and expense, procure and maintain commercial general liability insurance in amounts not less than
[****] per incident and [****] annual aggregate and naming the Indemnitees as additional insureds. During clinical trials of any such product, process or service, Licensee shall, at its sole 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 
cost and expense, procure and maintain commercial general liability insurance [****], naming the Indemnitees as additional insureds. Such commercial general liability insurance shall provide:
(a) product liability coverage and (b) broad form contractual liability coverage for Company’s indemnification under this Agreement. 

10.2.2. [****]. 

10.2.3. Licensee shall provide Harvard with written evidence of such insurance upon request of Harvard. Licensee shall provide
Harvard with written notice at least fifteen (15) days prior to the cancellation, non-renewal or material change in such insurance; if Licensee does not obtain replacement insurance providing comparable coverage within such fifteen
(15) day period, Licensee shall have the right to terminate this Agreement effective at the end of such fifteen (15) day period without notice or any additional waiting periods. 

10.2.4. Licensee shall maintain such commercial general liability insurance beyond the expiration or termination of this
Agreement during: (a) [****] and (b) [****]. 
 10.3 Additional [****]. 

10.3.1. [****]. 

10.3.2. [****]. 
  

	11.	Term and Termination. 

 11.1. Term. The term of this Agreement shall
commence on the Effective Date and, unless earlier terminated as provided in this Section 11, shall continue in full force and effect on a Licensed Product-by-Licensed Product and country-by-country basis until the expiration of all payment
obligations pursuant to Section 6 for such Licensed Product. 
 11.2. Termination. 

11.2.1. Termination Without Cause. Licensee may terminate this Agreement upon sixty (60) days’ prior written
notice to Harvard. 
 11.2.2. Termination for Default. 

11.2.2.1. In the event that either party commits a material breach of its obligations under this Agreement and fails to cure
that breach within ninety (90) days after receiving written notice thereof, the other party may terminate this Agreement immediately upon written notice to the party in breach. 

11.2.2.2, If Licensee defaults in its obligations under Section 10.2 to procure and maintain insurance or, if Licensee
has in any event failed to comply with the notice requirements contained therein, then Harvard may terminate this Agreement immediately without notice or additional waiting period. 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 11.2.3. Bankruptcy. Harvard may terminate this Agreement upon notice to Licensee
if Licensee becomes insolvent, is adjudged bankrupt, applies for judicial or extra-judicial settlement with its creditors, makes an assignment for the benefit of its creditors, voluntarily files for bankruptcy or has a receiver or trustee (or the
like) in bankruptcy appointed by reason of its insolvency, or in the event an involuntary bankruptcy action is filed against Licensee and not dismissed within ninety (90) days, or if the other party becomes the subject of liquidation or
dissolution proceedings or otherwise discontinues business. 
 11.3. Effect of Termination. 

11.3.1. Termination of Rights. Upon termination of this Agreement by either party pursuant to any of the provisions of
Sections 5.4 or 11.2: (a) the rights and licenses granted to Licensee under Section 4 shall terminate and all rights in and to and under the Licensed Patent Rights shall revert to Harvard; and (b) any existing agreements that contain
a Sublicense shall terminate to the extent of such Sublicense. 
 11.3.2. Accruing Obligations. Termination of this
Agreement shall not relieve the parties of obligations occurring prior to such termination, including obligations to pay amounts accruing hereunder up to the date of termination. 

11.4. Survival. The parties’ respective rights, obligations and duties under Sections 7.3, 7.5, 9.1, 9.3, 10, 11.3,
12.3 and 12.6, as well as any rights, obligations and duties which by their nature extend beyond the expiration or termination of this Agreement, shall survive any expiration or termination of this Agreement. In addition, Licensee’s obligations
under Sections 6.4.1(d) and 7 with respect to Type D Licensed Products shall survive termination. 
  

	12.	Miscellaneous. 

 12.1. [****]. 

12.2. No Security Interest. Licensee shall not enter into any agreement under which Licensee grants to or otherwise creates in
any third party a security interest in this Agreement or any of the rights granted to Licensee herein. Any grant or creation of a security interest purported or attempted to be made in violation of the terms of this Section 12.2 shall be null
and void and of no legal effect. 
 12.3. Use of Name. Licensee shall not, and shall ensure that its Affiliates and
Sublicensees shall not, use the name or insignia of Harvard or the name of any of Harvard officers, faculty, other researchers or students, or any adaptation of such names, in any advertising, promotional or sales literature, including without
limitation any press release or any document employed to obtain funds, without the prior written approval of Harvard. This restriction shall not apply to any information required by law to be disclosed to any governmental entity. 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 12.4. Entire Agreement. This Agreement is the sole agreement with respect to the
subject matter hereof and except as expressly set forth herein, supersedes all other agreements and understandings between the parties with respect to the same. 

12.5. Notices. Unless otherwise specifically provided, all notices required or permitted by this Agreement shall be in writing
and may be delivered personally, or may be sent by facsimile or certified mail, return receipt requested, to the following addresses, unless the parties are subsequently notified of any change of address in accordance with this Section 12.5:

  

					
	If to Licensee:	  	 Raindance Technologies, Inc.
 530 Whitfield
Street
 Guilford, CT 06437
 Attn.: Jonathan Rothberg
	  	
		
	If to Harvard:	  	 Office of Technology Development

Harvard University
 Holyoke Center 727

1350 Massachusetts Avenue
 Cambridge, MA 02138

Attn.: Chief Technology Development Officer

 Any notice shall be deemed to have been received as follows: (i) by personal delivery, upon receipt;
(ii) by facsimile, one business day after transmission or dispatch; (iii) by airmail, seven (7) business days after delivery to the postal authorities by the party serving notice. If notice is sent by facsimile, a confirming copy of
the same shall be sent by mail to the same address. 
 12.6. Governing Law and Jurisdiction. This Agreement will be governed
by, and construed in accordance with, the substantive laws of the Commonwealth of Massachusetts, without giving effect to any choice or conflict of law [****]. Any dispute will be resolved by the state courts of the Commonwealth of Massachusetts or
the federal courts of the District of Massachusetts, without restricting any right of appeal. 
 12.7. Binding Effect.
This Agreement shall be binding upon and inure to the benefit of the parties and their respective legal representatives, successors and permitted assigns. 

12.8. Headings. Section and subsection headings are inserted for convenience of reference only and do not form a part of this
Agreement. 
 12.9. Counterparts. This Agreement may be executed simultaneously in two or more counterparts, each of
which shall be deemed an original. 
 12.10. Amendment; Waiver. This Agreement may be amended, modified, superseded or
canceled, and any of the terms may be waived, only by a written instrument executed by each party or, in the case of waiver, by the party waiving compliance. The delay or failure of any party at any time or times to require performance of any
provisions hereof shall in no manner  

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 
affect the rights at a later time to enforce the same. No waiver by either party of any condition or of the breach of any term contained in this Agreement, whether by conduct, or otherwise, in
any one or more instances, shall be deemed to be, or considered as, a farther or continuing waiver of any such condition or of the breach of such term or any other term of this Agreement. 

12.11. No Agency or Partnership. Nothing contained in this Agreement shall give any . party the right to bind another, or be
deemed to constitute either parties as agents for each other or as partners with each other or any third party. 
 12.12.
Assignment and Successors. This Agreement may not be assigned by either party without the consent of the other, which consent shall not be unreasonably withheld, except that each party may, without such consent, assign this Agreement and the
rights, obligations and interests of such party to any of its Affiliates, to any purchaser of all or substantially all of its assets or research to which the subject matter of this Agreement relates, or to any successor corporation resulting from
any merger or consolidation of such party with or into such corporation. 
 12.13. Force Majeure. Neither party will be
responsible for delays resulting from causes beyond the reasonable control of such party, including without limitation fire, explosion, flood, war, strike, or riot; provided that the nonperforming party uses commercially
reasonable efforts to avoid or remove such causes of nonperformance and continues performance under this Agreement with reasonable dispatch whenever such causes are removed. 

12.14. Interpretation. The parties hereto acknowledge and agree that: (i) each Party and its counsel reviewed and
negotiated the terms and provisions of this Agreement and have contributed to its revision; (ii) the rule of construction to the effect that any ambiguities are resolved against the drafting party shall not be employed in the interpretation of
this Agreement; and (iii) the terms and provisions of this Agreement shall be construed fairly as to both parties hereto and not in favor of or against either party, regardless of which party was generally responsible for the preparation of
this Agreement. 
 12.15. Severability. If any provision of this Agreement is or becomes invalid or is ruled invalid by
any court of competent jurisdiction or is deemed unenforceable, it is the intention of the parties that the remainder of this Agreement shall not be affected. 
  

[Remainder of page intentionally left blank] 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly
authorized representatives as of the date first written above. 
  

									
	President and Fellows of Harvard College	 		 	Raindance Technologies, Inc.
					
	By:	 	/s/ Isaac T. Kohlberg	 		 	By:	 	/s/ Jonathan M. Rothberg
		 	 Name: Isaac T. Kohlberg
 Title: Senior Associate
Provost
	 		 		 	 Name: Jonathan M. Rothberg
 Title: Chairman
of the Board

		 	 Chief Technology Development Officer
 Office of
Technology Development
 Harvard University
	 		 		 	

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 Exhibit 1.3 

Development Milestones 

RainDance Technologies—[****] 

[****] 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 Exhibit 1.4 

Development Plan 

RainDance Technologies—[****] 

[****] 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 Exhibit 1.5 

Exclusive Harvard Patent Rights 

[****] 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 Exhibit 1.7 

Harvard Case [****] Patent Rights 

[****] 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 Exhibit 1.8 

Harvard Case [****] Patent Rights 

[****] 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 Exhibit 1.9 

Harvard Case [****] Patent Rights 

[****] 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 Exhibit 1.10 

Harvard [****] Patent Rights 

[****] 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 Exhibit 1.17 

Non-Exclusive Harvard Patent Rights 

[****] 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 Exhibit 6.2.1.2 

Raindance Capitalization Table 

[****] 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 Amendment Agreement 

THIS AMENDMENT AGREEMENT is entered into as of this 26th day of September, 2006, by
and between Technologies, Inc., a Delaware corporation, having a principle place of business at 530 Whitfield Street, Guilford CT 06437 (“Licensee”) and President and Fellows of Harvard College, Holyoke Center, Suite 727,
1350 Massachusetts Avenue, Cambridge, MA (“Harvard”). 
 WHEREAS, the parties are party to a certain License Agreement
dated February 23, 2006 (the “License Agreement”); and 
 WHEREAS, the parties wish to clarify a matter regarding the
[****] of the License Agreement; and 
 WHEREAS, there is a typographical error in Section 4.1.1.3 of the License Agreement; and

 WHEREAS, in the next to final draft of the License Agreement, the patents and patent applications constituting the Harvard
Case [****] Patent Rights (as defined in the License Agreement) were taken out of the definition of “Non-Exclusive Harvard Patent Rights” (as defined in the License Agreement) and included as a separate definition; and 

WHEREAS, the parties have discovered that they inadvertently failed to include a separate license grant clause for the Harvard
Case [****] Patent Rights in the final draft of the License Agreement; and 
 WHEREAS, the parties wish to amend the License
Agreement to make such clarification, correct such typographical error and correct such inadvertent omission, all in accordance with the terms and conditions of this Amendment Agreement. 

NOW, THEREFORE, the parties hereto, intending to be legally bound, hereby agree as follows: 

1. The following shall be added at the end of Section 3.3.2 of the License Agreement: 

[****] 
 2. In
Section 4.1,13 of the License Agreement, the reference to “Section 4.1.1.3 below” in the parenthetical shall be changed to “Section 4.1.1.4 below”. 

3. The following shall be added as Section 4.1.2.3 of the License Agreement: 

“4.1.2.3. Harvard Case [****] Patent Rights. Subject to the terms and conditions set forth in this Agreement, Harvard hereby grants
to Licensee a non-exclusive, worldwide, royalty-bearing license under the Harvard Case [****] Patent Rights solely to [****]. 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 4. All other terms and conditions of the License Agreement shall remain unchanged and in full
force and effect. 
 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized
representatives as of the date first written above. 
  

									
	President and Fellows of Harvard College	  		  	Rain dance Technologies, Inc.
					
	By:	 	 /s/ Isaac T. Kohlberg
	  		  	By:	  	 /s/ Jonathan M. Rothberg

		 	 Name: Isaac T. Kohlberg
 Title: Senior Associate
Provost
 Chief Technology Development Officer
 Office of
Technology Development
 Harvard University
	  		  		  	 Name: Jonathan M. Rothberg
 Title:
Chairman

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 Amendment No. 2 

This Amendment No. 2 is entered into as of this 25th day of August, 2011 (the
“Amendment No. 2 Effective Date”), by and between RainDance Technologies, Inc., a Delaware corporation, having a principle place of business at 44 Hartwell Avenue, Lexington, MA 02421 (“Licensee”) and President and
Fellows of Harvard College, having an office at Holyoke Center, Suite 727, 1350 Massachusetts Avenue, Cambridge, MA 02138 (“Harvard”). 

WHEREAS, the parties entered into that certain License Agreement effective as of February 23, 2006, as amended on
September 26, 2006 (the “License Agreement”), pursuant to which Harvard granted licenses to Licensee under certain patent rights; 

WHEREAS, the technology claimed in the Harvard Case [****] Patent Rights (as defined below) was developed in research conducted by
Harvard researcher Dr. [****]; Licensee wishes to obtain a license under the Harvard Case [****] Patent Rights and Harvard desires to have products based on the inventions described in the Harvard Case [****] Patent Rights developed
and commercialized to benefit the public; Licensee has represented to Harvard, in order to induce Harvard to enter into this Amendment No. 2, that Licensee shall commit itself to commercially reasonable efforts to develop, obtain regulatory
approval for (if needed) and commercialize such products; 
 WHEREAS, with respect to the Harvard Case [****] Patent Rights (as
defined in the License Agreement), Harvard has [****] and therefore Harvard is now able to grant Licensee exclusive rights in the Harvard Case [****] Patent Rights as referenced in Section 4.1.2.2 of the License Agreement; 

WHEREAS, with respect to the Harvard [****] Patent Rights (as defined in the License Agreement), Licensee has [****] and 

WHEREAS, the parties wish to amend the License Agreement in accordance with the terms and conditions of this Amendment No. 2 to:
(a) add an exclusive license grant under the Harvard Case [****] Patent Rights thereto; (b) convert the license granted under the Harvard Case [****] Patent Rights from non-exclusive to exclusive and [****]; and (c) [****]
with respect to the license granted under the Harvard [****] Patent Rights; 
 NOW, THEREFORE, the parties hereto, intending to be
legally bound, hereby agree as follows: 
 1. As used herein, “Harvard Case [****] Patent Rights” shall mean, in each case to
the extent owned and controlled by Harvard, Harvard’s interest in: (a) the patent applications and patents listed in Exhibit 1.5 to this Amendment No. 2 and designated as Harvard Case [****] therein; (b) any patent or
patent application that claims priority to and is a divisional, continuation, reissue, renewal, reexamination, substitution or extension of at least one of the patents or patent applications identified in (a); (c) any patents issuing on any of
the patent applications identified in (a) or (b); (d) any claim of a continuation-in-part application or patent, 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 
which claim is entitled to the priority date of, and is directed at subject matter described in, at least one of the patents or patent applications identified in (a), (b) or (c); and
(e) any foreign counterpart of any of the patents or patent applications identified in (a), (b) or (c) or of the claims identified in (d). 

2. Exhibit 1.5 of the License Agreement is hereby replaced it its entirety with Exhibit 1.5 to this Amendment No. 2, the effect of
which is to add the Case [****] Patent Rights and Case [****] Patent Rights to the definition of “Exclusive Harvard Patent Rights” in the License Agreement. Based on this addition, the parties acknowledge that each instance of
the phrase “Harvard Case [****] Patent Rights” in the following Sections of the License Agreement is now redundant: 1.11, 2 and 3.1. In addition, each instance of the phrase “Harvard Case [****] Patent Rights” is hereby
deleted from Section 3.3.2 of the License Agreement. 
 3. Section 1.6 of the License Agreement is hereby replaced in its entirety
with the following: 
 “1.6. “Field” shall mean: 

1.6.1. [****] and 

1.6.2. [****]. 

4. The words [****] are hereby deleted from the end of Section 4.1.1.2 of the License Agreement. 

5. Reserved. 
 6.
Section 4.1.2.2 of the License Agreement is hereby deleted in its entirety. 
 7. Licensee shall [****] as follows: 

(a) [****] and 

(b) [****]. 

    [****]. 

8. Harvard hereby acknowledges the following updated notice address for Licensee pursuant to Section 12.5 of the License Agreement: 

 

							
	             If to Licensee:
	  	 RainDance Technologies, Inc.
 44 Hartwell
Avenue
 Lexington, MA 02421
 Attention: CEO

Fax: 781.861.1233
	  		  	

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 9. Except as expressly set forth above, all other terms and conditions of the License Agreement
shall remain unchanged and continue in full force and effect. This Amendment No. 2 amends and is hereby made a part of the License Agreement. 

10. The parties may execute this Amendment No. 2 in counterparts, each of which is deemed an original, but all of which together
constitute one and the same amendment. This Amendment No. 2 may be delivered electronically or by facsimile transmission, and electronic or facsimile copies of executed signature pages shall be as binding as originals. 

IN WITNESS WHEREOF, the parties have caused this Amendment No. 2 to be executed by their duly authorized representatives as of the
Amendment No. 2 Effective Date. 
  

							
	President and Fellows of Harvard College	  	Rain dance Technologies, Inc.
				
	By:	  	 /s/ Cris Rothfuss
	  	By:	  	 /s/ S. Roopom Banerjee

		  	Name: Cris Rothfuss	  		  	Name: S. Roopom Banerjee
		  	Title: Director of Technology Transactions	  		  	Title: President and Chief Executive Officer
		  		  		  	

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  

 Exhibit 1.5 

Exclusive Harvard Patent Rights 

[****] 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION.EX-10.24

 Exhibit 10.24 

COEXCLUSIVE 
 PATENT
LICENSE AGREEMENT 
 For 

NUCLEIC ACID DETECTION AND ANALYSIS 

For 
 All Fields of Use

 Between 

LAWRENCE LIVERMORE NATIONAL SECURITY, LLC 

and 
 RAINDANCE
TECHNOLOGIES, INC. 
 LLNL Case No. TL02294-0.0 

Lawrence Livermore National Laboratory 

P.O. Box 808, L-795, Livermore, CA 94551 

Industrial Partnerships Office 

August 20, 2008 
 CONFIDENTIAL
TREATMENT REQUESTED UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL
TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 TABLE OF CONTENTS 

 

							
	 1.
	 	BACKGROUND	  	 	3	  
			
	 2.
	 	DEFINITIONS	  	 	5	  
			
	 3.
	 	LICENSE GRANT	  	 	11	  
			
	 4.
	 	SUBLICENSING RIGHTS AND OBLIGATIONS	  	 	11	  
			
	 5.
	 	FEES, ROYALTIES, AND PAYMENTS	  	 	12	  
			
	 6.
	 	DUE DILIGENCE	  	 	14	  
			
	 7.
	 	ROYALTY AND PROGRESS REPORTS	  	 	16	  
			
	 8.
	 	BOOKS AND RECORDS	  	 	18	  
			
	 9.
	 	LIFE OF THE AGREEMENT	  	 	18	  
			
	 10.
	 	TERMINATION	  	 	19	  
			
	 11.
	 	DISPOSITION OF LICENSED PRODUCTS ON HAND UPON TERMINATION	  	 	20	  
			
	 12.
	 	PATENT PROSECUTION AND MAINTENANCE	  	 	21	  
			
	 13.
	 	PATENT INFRINGEMENT	  	 	21	  
			
	 14.
	 	USE OF NAMES AND TRADEMARKS	  	 	22	  
			
	 15.
	 	LIMITED WARRANTY	  	 	22	  
			
	 16.
	 	INDEMNIFICATION	  	 	23	  
			
	 17.
	 	INSURANCE	  	 	24	  
			
	 18.
	 	WAIVER	  	 	25	  
			
	 19.
	 	ASSIGNABILITY	  	 	25	  
			
	 20.
	 	LATE PAYMENTS	  	 	25	  
			
	 21.
	 	NOTICES	  	 	26	  
			
	 22.
	 	GOVERNING LAWS; VENUE; ATTORNEYS FEES	  	 	27	  
			
	 23.
	 	PATENT MARKING	  	 	27	  
			
	 24.
	 	GOVERNMENT APPROVAL OR REGISTRATION	  	 	27	  
			
	 25.
	 	COMPLIANCE WITH LAWS	  	 	28	  
			
	 26.
	 	FORCE MAJEURE	  	 	28	  
			
	 27.
	 	[****]	  	 	29	  
			
	 28.
	 	MISCELLANEOUS	  	 	29	  
		
	 EXHIBIT A—LICENSED PATENTS
	  	 	31	  
		
	 EXHIBIT B—RIGHTS GRANTED AND PERFORMANCE OBLIGATIONS
	  	 	32	  
		
	 EXHIBIT C—FEES AND ROYALTIES
	  	 	34	  
		
	 EXHIBIT D—MUTUAL NONDISCLOSURE AGREEMENT
	  	 	36	  

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 2 

 COEXCLUSIVE PATENT LICENSE AGREEMENT 

For NUCLEIC ACID DETECTION AND ANALYSIS 

For All Fields of Use 
 This license
agreement (“Agreement”) is effective on the Effective Date by and between Lawrence Livermore National Security, LLC (“LLNS”) under its U.S. Department of Energy (“DOE”) Contract No. DE-AC52-07NA27344 to manage and
operate Lawrence Livermore National Laboratory (“LLNL”), and RainDance Technologies, Inc. (“LICENSEE”), a Delaware corporation having its principal place of business at 44 Hartwell Avenue, Lexington, MA 02421. LLNS is a
limited liability company incorporated in the State of Delaware, with its principal office at 1658 Holmes Street, Livermore, CA 94550-6010. LLNS and LICENSEE are referred to jointly as “Parties.” This Agreement and the resulting
license are subject to overriding obligations to the Federal Government pursuant to the provisions of LLNS’s Contract No. DE-AC52-07NA27344 with the DOE for the operation of the LLNL and DOE’s grant of patent rights to LLNS. 

 

	1.	BACKGROUND 

  

	1.1	Certain inventions characterized as Fluid-Partitioned DNA Detection (“Invention”) described in LLNL patent applications and patents listed in Exhibit A (LICENSED PATENTS), which may be useful for the
production of instruments performing rapid nucleic acid amplification and detection, were made at LLNL and are covered by LLNS’s Patent Rights as defined in Article 2 (DEFINITIONS). 

 

	1.2	LICENSEE entered into a Mutual Nondisclosure Agreement executed by the Parties on February 26, 2008 as amended by the Parties on April 17, 2008 and further amended by the Parties on April 29, 2008
attached hereto as Exhibit D (MUTUAL NONDISCLOSURE AGREEMENT), which is incorporated herein, that allowed LICENSEE to evaluate its interest in taking a license to the Invention. 

 

	1.3	LLNS grants to the U.S. Government a nontransferable, paid-up, nonexclusive, irrevocable license to use the Invention by, or on behalf of, the U.S. Government throughout the world. 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 3 

	1.4	LICENSEE requested certain rights from LLNS to commercialize the Invention. 

  

	1.5	LLNS wishes to respond to LICENSEE’s request by granting the following rights to LICENSEE so that the products and other benefits derived from the Invention can be enjoyed by the general public.

  

	1.6	The scope of such rights granted by LLNS is intended to extend to the scope of the patents and patent applications pertaining to the Invention, but only to the extent that LLNS has Valid Claims of such Patent Rights.

  

	1.7	LLNS has informed LICENSEE and LICENSEE understands that the Invention is a research product from a national laboratory and requires additional development for its commercialization. LICENSEE agrees
it is responsible for the additional development of the Invention for commercialization purposes. 

  

	1.8	LICENSEE is a “small entity” as defined in 37 CFR § 1.27. 

  

	1.9	LICENSEE is a “small business firm” as defined at Section 2 of Pub. L. 85-536 (15 U.S.C. § 632). 

  

	1.10	Both Parties recognize that earned royalties due under this Agreement will be based on LICENSEE’s last act of infringement of Patent Rights within the control of LICENSEE, regardless of whether
LICENSEE had control over prior infringing acts. 

  

	1.11	The Parties intend that royalties due under this Agreement will be calculated and paid on Sales of the final product or service by LICENSEE. 

 

	1.12	LICENSEE recognizes the need to practice due diligence in the development of the patents licensed under this agreement to maintain the license. In addition, both Parties acknowledge that the U.S. Government has
certain march-in rights in accordance with 48 CFR 27.304-1 (g) and 15 USC 3710a(b)(l)(B) and (C). 

  

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 4 

	1.13	LICENSEE is one of two (2) licensees to be granted coexclusive rights under Licensed Patents (each, a “Coexclusive Licensee”). LICENSEE understands that upon termination of either of
Coexclusive Licensee’s rights in and to Licensed Patents, those coexclusive rights will [****], as described in Paragraph B.4, provided that LICENSEE is in compliance with the terms and conditions of this Agreement. 

THEREFORE, the Parties agree as follows: 
  

	2.	DEFINITIONS 

 As used in this Agreement, the following terms, whether used in the
singular or plural, will have the following meanings: 
  

	2.1	“Affiliate” of LICENSEE means any entity which, directly or indirectly, Controls LICENSEE, is Controlled by LICENSEE, or is under common Control with LICENSEE. “Control”
means (i) having the actual, present capacity to elect a majority of the directors of such affiliate, (ii) having the power to direct more than fifty percent (50%) of the voting rights entitled to elect directors, or (iii) in any
country where the local law will not permit foreign equity participation of a majority, ownership or control, directly or indirectly, of the maximum percentage of such outstanding stock or voting rights permitted by local law. LICENSEE does
not include “Affiliate.” 

  

	2.2	“Coexclusive” means rights within Fields of Use granted by LLNS to a maximum of two (2) licensees. 

  

	2.3	“Diligent Efforts” means such efforts and resources as are commonly used in the life sciences industry for an instrument of similar commercial potential, taking into consideration the cost to develop and
commercialize the product, the risks inherent in the development and commercialization of the product, its competitiveness compared to alternative products, the proprietary position of the product, the profitability of the product and all other
relevant factors. 

  

	2.4	“Effective Date” means the date of execution by the last signing Party and payment of the first installment of the License Issue Fee. 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 5 

	2.5	“Fields of Use” is the application or use defined in Exhibit B (RIGHTS GRANTED AND PERFORMANCE OBLIGATIONS). 

  

	2.6	“Joint Venture” means any separate entity established pursuant to a written agreement between a third party and LICENSEE, or to constitute a vehicle for a joint effort, in which the separate entity
manufactures, uses, purchases, Sells, or acquires Licensed Products from LICENSEE. LICENSEE does not include “Joint Venture.” 

  

	2.7	“Licensed Method” means any process or method the use or practice of which, but for the license granted in this Agreement, would infringe, or contribute to, or induce the infringement of, any Patent Rights.

  

	2.8	“Licensed Patents” means: 

  

	 	2.8.1	U.S. patents and U.S. patent applications specified in Exhibit A (LICENSED PATENTS), and U.S. patents resulting from these applications, continuations of these applications, divisionals, and continuation-in-part
applications resulting from these applications only to the extent, however, that Valid Claims in the continuation-in-part applications are entirely supported in the specification and entitled to the priority date of the parent application;

  

	 	2.8.2	reissues of 2.8.1 and any continuations, divisionals, and continuation-in-part applications (but only to the extent, however, that Valid Claims in the continuation-in-part applications are entirely supported in the
specification of the parent reissue patent and entitled to the priority date thereof) of such reissues. 

  

	2.9	“Licensed Product” means all kits, compositions of matter, materials, articles of manufacture, and products the manufacture, use, Sale, offer for Sale, or import of which, but for the license granted in this
Agreement, would infringe, or contribute to or induce the infringement of any Patent Rights were they issued at the time of infringement in that country, or would require the performance of the Licensed Method. For clarity, “Licensed
Product” shall not include any reagents including buffers, enzymes, solutions, primers, primer libraries, nucleic acids, oligonucleotides, probes and labels associated with commercialization of the Invention where such reagents or consumables
do not infringe a Valid Claim. 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 6 

	2.10	“Licensed Service” means the use of Licensed Products or Licensed Method to provide a service. Notwithstanding the foregoing, if LICENSEE or a sublicensee is practicing a Licensed Method or using a Licensed
Product for purposes of developing a Licensed Product for commercialization, then the practice of such Licensed Method or use of such Licensed Product shall not constitute a Licensed Service for purposes of this Agreement. 

 

	2.11	“Net Invoice Price” means the gross invoice price charged and the value of any other consideration received by LICENSEE for the Sale of a Licensed Product or Licensed Service, less the following items, but
only to the extent that they actually pertain to the Sale of such Licensed Product or Licensed Service, and are separately billed: 

  

	 	2.11.1	Allowances for Uncollectible Amounts with respect to the gross invoice price charged determined in accordance with generally accepted accounting principles (“GAAP”) consistently applied by the LICENSEE
and/or any sublicensee and not to exceed [****] of such gross invoice price charged; for clarity and by way of example to illustrate the [****] limit on LICENSEE with respect to LICENSEE’s right to deduct Uncollectible Amounts in
accordance with this Subparagraph 2.11.1, if LICENSEE sells [****] of Licensed Product in a particular [****] period, then LICENSEE would be entitled to deduct up to a maximum of [****] for Uncollectible Amounts and the Net Invoice
Price would be adjusted accordingly; 

  

	 	2.11.2	Allowances actually granted to customers for rejections, returns, and prompt payment and volume discounts; 

  

	 	2.11.3	Freight, transport packing, insurance charges associated with transportation; and 

  

	 	2.11.4	Taxes, including Deductible Value Added Tax, tariffs or import/export duties based on Sales when included in the gross invoice price, but not value-added taxes other than Deductible Value Added Tax or taxes assessed on
income derived from Sales. “Deductible Value Added Tax” means only the portion of the value added tax that is actually incurred and is not reimbursable, refundable or creditable under the tax authority of any country; and

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 7 

	 	2.11.5	Rebates and discounts paid or credited required by applicable law. 

 In no event shall more than one royalty be
due to LLNS with respect to any Licensed Product or Licensed Service unit, regardless of the number of Valid Claims within the Patent Rights applicable to such Licensed Product or Licensed Service, or the number of transfers of such product. In no
event shall a royalty be payable under this Agreement with respect to the sale or the provision of Licensed Products for use in clinical trials conducted for purposes of obtaining regulatory approvals for Licensed Products, as samples or for
research and development efforts by or on behalf of LICENSEE that are not a full commercial sale, or with respect to any Licensed Products used by LICENSEE, its Affiliates or sublicensees in the development, manufacture or testing of
Licensed Products. 
  

	2.12	“Net Sale” means the Net Invoice Price, except in the instances described in Subparagraphs (2.12.1), (2.12.2), (2.12.3), and (2.12.4) of this Paragraph. 

 

	 	2.12.1	For any Relationship-Influenced Sale of a Licensed Product or Licensed Service, Net Sales will be based on the Net Invoice Price at which the Relationship-Influenced Sale Purchaser resells such Licensed Product or
Licensed Service; 

  

	 	2.12.2	In those instances where Relationship-Influenced Sale Purchaser combines such Licensed Product or Licensed Service in any manner with any other product or service, Net Sales will be the Net Invoice Price of the combined
product or service; 

  

	 	2.12.3	 In those instances where Licensed Product or Licensed Service is not Sold, but is otherwise exploited, the Net Sales for such Licensed Product or
Licensed Service will be the Net Invoice Price of products or services of similar kind and quality, Sold in similar quantities, currently being offered for Sale by LICENSEE, its Affiliate and/or any sublicensee. Where such products or
services are not 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 8 

	 	
currently being offered for Sale by LICENSEE, its Affiliate and/or any sublicensee, the Net Sales for Licensed Product or Licensed Service otherwise exploited, for the purpose of computing
royalties, will be the average Net Invoice Price at which products or services of similar kind and quality, Sold in similar quantities, are then currently being offered for Sale by other manufacturers. Where such products or services are not
currently Sold or offered for Sale by LICENSEE, its Affiliates and/or any sublicensees, or others, then the Net Sales will be LICENSEE’s, its Affiliates and/or any sublicensee’s cost of manufacture of Licensed Product or the
cost of conducting the service, determined by LICENSEE’s, its Affiliates and/or any sublicensee’s customary accounting procedures, plus [****]; 

  

	 	2.12.4	In those instances where LICENSEE, an Affiliate or a sublicensee acquires and subsequently Sells Licensed Product or Licensed Service previously Sold by LICENSEE, Net Sales will mean the Net Invoice Price
upon Sale of such acquired Licensed Product by LICENSEE or the sublicensee, less any amounts paid to LLNS on account of earlier Sale or other exploitation of the acquired Licensed Product. 

 

	2.13	“New Developments” means inventions, or claims to inventions, which constitute advancements, developments or improvements, whether or not patentable and whether or not the subject of any patent application,
which are not sufficiently supported by the specification of a previously-filed patent or patent application within the Patent Rights to be entitled to the priority date of the previously-filed patent or patent application. 

 

	2.14	“Patent Rights” means the Valid Claims of, to the extent assigned to, or otherwise obtained by, LLNS, in Licensed Patents. This definition of Patent Rights excludes any rights in and to New Developments.

  

	2.15	 “Related Party” means a corporation, firm or other entity with which, or individual with whom, LICENSEE and/or any sublicensee (or
any of their respective stockholders, subsidiaries or Affiliates) have an agreement, understanding, or arrangement (for 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 9 

	 	
example, but not by way of limitation, an option to purchase stock or other equity interest, or an arrangement involving a division of revenue, profits, special discounts, rebates, or allowances)
unrelated to the Sale of the Licensed Products or Licensed Services without which such other agreement, understanding, or arrangement, the amounts, if any, charged by LICENSEE or sublicensee to such entity or individual for the Licensed
Product or Licensed Service would be higher than the Net Invoice Price actually received, or if such agreement, understanding, or arrangement results in LICENSEE or sublicensee extending to such entity or individual lower prices for such
Licensed Product or Licensed Service than those charged to others without such agreement, understanding, or arrangement buying similar products or services in similar quantities. 

 

	2.16	“Relationship-Influenced Sale” means a Sale of a Licensed Product or Licensed Service, by LICENSEE, an Affiliate and/or any sublicensee to (i) an Affiliate; (ii) a Joint Venture; or
(iii) a Related Party. 

  

	2.17	“Relationship-Influenced Sale Purchaser” means the purchaser of Licensed Product or Licensed Service in a Relationship-Influenced Sale. 

 

	2.18	“Sale” means the act of selling, leasing or otherwise transferring, providing, or furnishing for use for any consideration. Correspondingly, “Sell” means to make or cause to be made a Sale, and
“Sold” means to have made or caused to be made a Sale. 

  

	2.19	“Uncollectible Amounts” means amounts owed and unpaid to LICENSEE or a sublicensee for previously Sold Licensed Products, which LICENSEE or the sublicensee has attempted to collect, using efforts
at least as diligent as those efforts that LICENSEE or the sublicensee (as applicable) uses in attempting to collect other overdue debts, provided that such amounts have been formally designated as such in accordance with
LICENSEE’s or sublicensee’s internal accounting procedures and provided further that such allowance shall not be applicable in the event and to the extent any such designated amounts are ultimately collected. 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 10 

	2.20	“Valid Claim” means a claim of a patent or patent application in any country that (i) has not expired; (ii) has not been disclaimed; (iii) has not been cancelled or superseded, or if cancelled
or superseded, has been reinstated; and (iv) has not been revoked, held invalid, or otherwise declared unenforceable or not allowable by a tribunal or patent authority of competent jurisdiction over such claim in such country from which no
further appeal has or may be taken. 

  

	3.	LICENSE GRANT 

  

	3.1	The license rights granted to LICENSEE by LLNS are set forth in Exhibit B (RIGHTS GRANTED AND PERFORMANCE OBLIGATIONS). 

  

	3.2	The license granted hereunder will be subject to the overriding obligations to the U.S. Government including those set forth in 35 U.S.C. §200-212 and applicable governmental implementing regulations and the
obligation to report on utilization of the Invention set forth in 37 CFR §401.14(h). 

  

	3.3	Nothing in this Agreement will be deemed to limit the right of LLNS to publish any and all technical data resulting from any research performed by LLNS relating to the Invention and to make, use or practice the
Invention, Licensed Product, Licensed Service, Licensed Method, and associated technology, and allow other educational and non-profit institutions to do so for educational and research purposes. 

 

	4.	SUBLICENSING RIGHTS AND OBLIGATIONS 

  

	4.1	The sublicensing rights granted to LICENSEE by LLNS are set forth in Exhibit B (RIGHTS GRANTED AND PERFORMANCE OBLIGATIONS), Paragraph B.2 (Sublicensing Rights). 

 

	4.2	LICENSEE must include in any sublicense all the rights and obligations due LLNS and the Government set forth in this Agreement. 

 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 11 

	4.3	LICENSEE must require sublicensees to provide it with copies of all progress reports and royalty reports in accordance with the provisions of this Agreement, and LICENSEE will collect and deliver to LLNS
all such reports due from sublicensees. Any such reports shall be treated by LLNS as Proprietary Information in accordance with Exhibit D. 

  

	4.4	LICENSEE must include in all sublicenses the notice that upon termination of this Agreement for any reason, LLNS has the right with respect to a particular sublicensee to determine at the time of such termination
that such sublicensee is (i) in conformance with current export control policy, (ii) not from DOE’s Sensitive Country List, (iii) not on the U.S. Department of Commerce’s Denied Person’s List, and (iv) not from the
U.S. Department of State Embargoed Countries List. LICENSEE shall also include in each sublicense agreement an obligation on the part of the sublicensee to provide LLNS with all reasonable assistance necessary for LLNS to make such
determination at the written request of LLNS therefor. 

  

	4.5	LICENSEE will notify LLNS of each sublicense granted hereunder and provide LLNS with a complete copy of each executed sublicense agreement within thirty (30) days of issuance of the sublicense; provided
that, LICENSEE may redact from such copy information that is not related to compliance with this Agreement. 

  

	4.6	For the purposes of this Agreement, the operations of all sublicensees shall be deemed to be the operations of LICENSEE, for which LICENSEE shall be responsible. 

 

	4.7	Consideration owed to LLNS will be paid to LLNS on or before the due date of the royalty report applicable to the [****] in which consideration was due and owing to LICENSEE under the sublicense. LICENSEE
will collect from the sublicensees and will pay to LLNS all fees, royalties, and the cash equivalent of any consideration due LLNS. 

  

	5.	FEES, ROYALTIES, AND PAYMENTS 

  

	5.1	Fees and royalties due on Net Sales of Licensed Products or Licensed Services will be as specified in this Article 5, Exhibit C (FEES AND ROYALTIES), and Article 7 (ROYALTY AND PROGRESS REPORTS) of this Agreement.

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 12 

	5.2	As partial consideration for the rights granted to LICENSEE, LICENSEE will pay to LLNS the License Issue Fee as set forth in Exhibit C. 

 

	5.3	As partial consideration for all the rights granted to LICENSEE, LICENSEE will pay LLNS minimum annual royalties as set forth in Exhibit C. 

 

	5.4	As partial consideration for all the rights granted to LICENSEE, LICENSEE will pay to LLNS earned royalties at the rate set forth in Exhibit C. 

 

	5.5	Earned royalties shall accrue when Licensed Products or Licensed Services are invoiced, or if not invoiced, when delivered in a manner constituting a Net Sale as defined in Article 2 (DEFINITIONS), Paragraph 2.12.

  

	5.6	Payment for earned royalties will include all royalties accrued up to the last day of the most recently completed [****]. 

  

	5.7	All consideration due LLNS shall be payable in United States dollars. When Licensed Products or Licensed Services are sold for monies other than United States dollars, earned royalties will first be determined in the
foreign currency of the country in which such Licensed Products or Licensed Services were Sold and then converted into equivalent United States dollars. The exchange rate will be the average exchange rate quoted in the Wall Street Journal during the
last thirty (30) days of the reporting period. 

  

	5.8	Earned royalties on Sales of Licensed Products or Licensed Services occurring in any country outside the United States shall not be reduced by any taxes, fees, or other charges imposed by the government of such country
except those taxes, fees, and charges allowed under the provisions of Paragraph 2.12 (Net Sales). LICENSEE also will be responsible for all bank transfer charges. 

 

	5.9	Notwithstanding the provisions of Article 26 (FORCE MAJEURE), if at any time legal restrictions prevent prompt remittance of any earned royalties or other consideration owed to LLNS by LICENSEE with respect to
any country where a sublicense is issued or a Licensed Product or Licensed Service is Sold, then LICENSEE will convert the amount owed to LLNS into United States dollars and will pay LLNS directly from another source of funds in order to
remit the entire amount owed to LLNS. 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 13 

	5.10	No earned royalties will be collected or paid hereunder to LLNS on Licensed Products or Licensed Services Sold to the account of the U.S. Government. LICENSEE and its sublicensee will reduce the amount charged
for Licensed Products or Licensed Services Sold to the U.S. Government by an amount equal to the royalty for such Licensed Products or Licensed Services otherwise due LLNS. LICENSEE will provide LLNS with U.S. Government contract numbers and
a written statement by LICENSEE’s contracting officer that Sale of Licensed Products to the U.S. Government were reduced by the amount of royalty due LLNS. 

 

	5.11	If LLNS must pursue legal means to obtain payments owed by LICENSEE, LICENSEE will pay LLNS for all legal costs and any other related costs expended by LLNS to collect payments owed by LICENSEE.

  

	5.12	In the event that any patent or any claim thereof included within the Patent Rights is held invalid in a final decision by a court of competent jurisdiction and last resort and from which no appeal has or can be taken,
all obligation to pay royalties based on such patent or claim or any claim patentably indistinct therefrom will cease as of the date of such final decision. LICENSEE will not, however, be relieved from paying any royalties that accrued before
such final decision and LICENSEE will be obligated to pay the full amount of royalties due hereunder to the extent that LLNS licenses one or more Valid Claims within the Patent Rights to LICENSEE with respect to Licensed Products or
Licensed Services. 

  

	6.	DUE DILIGENCE 

  

	6.1	LICENSEE, upon execution of this Agreement, will use Diligent Efforts to proceed with the development, manufacture, and Sale of Licensed Products and Licensed Services and use of Licensed Methods, and will use
its Diligent Efforts to market the same after execution of this Agreement and in quantities sufficient to meet the market demands therefor. 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 14 

	6.2	LICENSEE will meet the specific performance obligations and milestones specified in Exhibit B (RIGHTS GRANTED AND PERFORMANCE OBLIGATIONS). If LICENSEE is unable to meet such milestones, LLNS will have the
right and option to: (a) [****]; (b) [****]; or (c) terminate this Agreement per Article 10 (TERMINATION), Paragraph 10.1 (Termination by LLNS). Nothing in this Paragraph 6.2 shall preclude the Parties from making use of the U.S.
Department of Energy’s ombuds program pursuant to the Technology Transfer Commercialization Act of 2000 to resolve any dispute not resolved by the Parties themselves if the Parties mutually agree to resolve any such dispute in accordance with
said Act. 

  

	6.3	LICENSEE will comply with all governmental laws and obtain all necessary governmental approvals in each country where Licensed Products or Licensed Services are manufactured, used, Sold, imported, or offered for
Sale. 

  

	6.4	During the term of this Agreement, LICENSEE will conduct normal, continuous business operations. If LICENSEE seeks protection under any United States bankruptcy proceedings during the term of this
Agreement, LICENSEE will notify LLNS in writing no later than seventy-two (72) hours after the bankruptcy filing. Unless the petition is dismissed in accordance with Paragraph 9.2, the license will automatically terminate.

  

	6.5	To exercise either the right to terminate this Agreement or [****] for lack of diligence required in this Article 6, LLNS will give LICENSEE written notice of the deficiency. LICENSEE thereafter has sixty
(60) days to cure the deficiency. If LLNS has not received written tangible evidence satisfactory to LLNS that the deficiency has been cured by the end of the sixty (60) day period, then LLNS may, at its option, terminate this Agreement
immediately without the obligation to provide sixty (60) days notice as set forth in Paragraph 10.1 or [****] by giving written notice to LICENSEE. Nothing in this Paragraph 6.5 shall preclude the Parties from making use of the U.S.
Department of Energy’s ombuds program pursuant to the Technology Transfer Commercialization Act of 2000 to resolve any dispute not resolved by the Parties themselves if the Parties mutually agree to resolve any such dispute in accordance with
said Act. 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 15 

	7.	ROYALTY AND PROGRESS REPORTS 

  

	7.1	LICENSEE will submit to LLNS an annual progress report as described in Paragraph 7.2 below covering activities by LICENSEE and its sublicensees related to the development and testing of all Licensed
Products and Licensed Services. After the first Sale of Licensed Product or Licensed Service, LICENSEE is required to submit a progress report annually rather than semi-annually. Such progress report will be signed by LICENSEE’s
President or his/her designee attesting to the accuracy of the information in the report. If LICENSEE fails to submit a timely progress report to LLNS, LLNS will be entitled to terminate this Agreement but only after LLNS has provided
LICENSEE notice of such failure and a reasonable opportunity to cure the failure, as provided in Paragraph 10.1 (Termination by LLNS). If either party terminates this Agreement before any Licensed Products or Licensed Services are Sold or
before this Agreement’s expiration, a final progress report covering the period prior to termination must be submitted within thirty (30) days of termination. 

 

	7.2	The progress reports submitted under Paragraph 7.1 above will include, but not be limited to, a reasonably detailed summary of the following topics: 

 

	 	•	 	Summary of work completed toward commercialization of Licensed Products or Licensed Services; 

  

	 	•	 	Schedule of anticipated events or milestones, including status of those events or milestones. Should LICENSEE wish to change the schedule of events or milestones specified in Exhibit B (RIGHTS GRANTED AND
PERFORMANCE OBLIGATIONS), LICENSEE must request advance written approval from LLNS; 

  

	 	•	 	A financial statement showing the investments made in the commercialization effort to date; 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 16 

	 	•	 	Anticipated and actual market introduction dates of each Licensed Product or Licensed Service; 

  

	 	•	 	Summary of marketing and sales activities, including copies of marketing and sales literature; and 

  

	 	•	 	activities of the sublicensees, if any. 

  

	7.3	LICENSEE also will report to LLNS the date of first Sale of a Licensed Product or Licensed Service within thirty (30) days of such Sale. 

 

	7.4	LICENSEE will [****] reports and payments to LLNS on or before each [****] of each year. If there were no Sale of Licensed Products or Licensed Services, the report will state that. Royalty reports will be signed
by LICENSEE’s President or Chief Financial Officer attesting to the accuracy of the report. Each such royalty report will cover the most recently completed [****] and will show: 

 

	 	7.4.1	the gross invoice prices and Net Sales of Licensed Products or Licensed Services Sold by LICENSEE and its sublicensees during the most recently completed [****]; 

 

	 	7.4.2	the number of Licensed Products or Licensed Services Sold by LICENSEE and its sublicensees during the most recently completed [****]; 

 

	 	7.4.3	the place of manufacture of Licensed Products or practice of Licensed Services; 

  

	 	7.4.4	the royalties, in U.S. dollars, payable hereunder with respect to Net Sales; 

  

	 	7.4.5	the method used to calculate the royalty, specifying all deductions taken and the dollar amount of each such deduction; and 

  

	 	7.4.6	the exchange rates used, if any. 

  

	7.5	Upon request, LICENSEE will provide LLNS with an audited statement of royalty accounts within sixty (60) days after the end of each calendar year. LLNS will protect such statements as Proprietary Information
of LICENSEE and not disseminate them unless required by law in accordance with the NDA. 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 17 

	7.6	[****]. 

  

	8.	BOOKS AND RECORDS 

  

	8.1	LICENSEE will keep books and records accurately showing all payments due LLNS and all Licensed Products manufactured (including place of manufacture), used, offered for Sale, imported, and/or Sold and all
Licensed Services performed received in connection therewith under the terms of this Agreement. Such books and records will be preserved for at least three (3) years after the date of the payment to which they pertain and will be open to
inspection by representatives or agents of LLNS during the normal business hours of LICENSEE and no more frequently than once per calendar year to determine their accuracy and assess LICENSEE’s compliance with the terms of this
Agreement. The results of such inspection and all data related thereto shall be deemed the Proprietary Information of LICENSEE in accordance with the NDA. 

  

	8.2	The fees and expenses of representatives of LLNS performing such an examination will be borne by LLNS. If, however, an error in royalties of more than [****] of the total royalties due for any year is discovered,
LICENSEE will bear the cost of the examination and will remit such underpayment to LLNS within thirty (30) days of the examination result. 

  

	8.3	[****] certified by either the Chief Executive Officer or Chief Financial Officer of LICENSEE, including [****]. Such [****] in which case LICENSEE shall [****]. LLNS will [****]. 

 

	9.	LIFE OF THE AGREEMENT 

  

	9.1	Unless otherwise terminated by operation of law, Paragraph 9.2, or by acts of the Parties in accordance with the terms of this Agreement, this Agreement will remain in effect from the Effective Date until the expiration
or abandonment of last of the Patent Rights licensed hereunder. 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 18 

	9.2	This Agreement will automatically terminate without the obligation to provide 60 days’ notice as set forth in Paragraph 10.1 (Termination by LLNS) ninety (90) days after a petition for relief under the United
States Bankruptcy Code is filed by or against the LICENSEE as a debtor or alleged debtor unless such petition is withdrawn or dismissed within such ninety (90) day period. 

 

	9.3	Any termination of this Agreement will not affect the rights and obligations set forth in the following Articles: Article 2 (DEFINITIONS), Article 5 (FEES, ROYALTIES, AND PAYMENTS), Article 8 (BOOKS AND RECORDS),
Article 9 (LIFE OF THE AGREEMENT), Article 11 (DISPOSITION OF LICENSED PRODUCTS ON HAND UPON TERMINATION), Article 14 (USE OF NAMES AND TRADEMARKS), Article 15 (LIMITED WARRANTY), Article 16 (INDEMNIFICATION), Article 17 (INSURANCE), Article 21
(NOTICES), Article 22 (GOVERNING LAWS; VENUE; ATTORNEYS’ FEES), and Article 28 (MISCELLANEOUS). 

  

	9.4	The termination or expiration of this Agreement will not relieve LICENSEE of its obligation to pay any fees, royalties, and reimbursements for foreign filing costs, or other payments owed to LLNS at the time of
such termination or expiration and will not impair any accrued right of LLNS. 

  

	10.	TERMINATION 

  

	10.1	Termination by LLNS: If LICENSEE fails to perform any material term or covenant of this Agreement, LLNS may give written notice to LICENSEE that if LICENSEE has not cured such failure within sixty
(60) days after the effective date of receipt of the notice, this Agreement will terminate at the end of such sixty (60) day period or at the end of such longer period as may be set forth in LLNS’s notice. 

 

	10.2	Termination by LICENSEE: LICENSEE will have the right at any time to terminate this Agreement by providing a Notice of Termination to LLNS and paying any outstanding fees owed LLNS. Termination of this
Agreement will be effective sixty (60) days after the date such notice takes effect. 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 19 

	10.3	This Agreement will terminate effective ten (10) days after the effective date of notice by LLNS, if LICENSEE ceases to carry on its business in its entirety. 

 

	10.4	Subject to LLNS determining that the criteria in Subparagraph 4.4 have been satisfied, for sublicensees in good standing with respect to their obligations under their applicable sublicense agreements with
LICENSEE, all sublicenses granted prior to termination shall survive, subject to the sublicensee agreeing in writing to be bound by the applicable terms and conditions of this Agreement including ongoing payment of royalties.

  

	11.	DISPOSITION OF LICENSED PRODUCTS ON HAND UPON TERMINATION 

  

	11.1	Upon termination of this Agreement, LICENSEE may Sell all previously made or partially made Licensed Products, but no additional Licensed Products, within a period of [****] after the date of termination,
provided, however, that the Sale of such Licensed Products will be subject to the terms of this Agreement including, but not limited to, the payment of earned royalties at the rates and at the times provided herein and the rendering of reports in
connection therewith. 

  

	11.2	Within thirty (30) days after termination of this Agreement by either Party, LICENSEE will provide LLNS with a written inventory of all Licensed Products in process of manufacture or in stock on the date of
termination. LICENSEE may complete Licensed Products in the process of manufacture at the time of termination, and may dispose of Licensed Products for [****] after the date of termination provided that LICENSEE pays royalties to LLNS
on such dispositions. At the conclusion of the [****] period, LICENSEE will destroy any remaining Licensed Products in stock or in process of manufacture and certify such destruction to LLNS. 

 

	11.3	LICENSEE may not practice Licensed Methods after the date of termination of this Agreement except as necessary to complete the manufacture of Licensed Products as permitted under Paragraph 11.2.

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 20 

	12.	PATENT PROSECUTION AND MAINTENANCE 

  

	12.1	[****]. LLNS and LICENSEE acknowledge that, as of the Effective Date [****]. 

  

	12.2	LICENSEE may request [****]. LICENSEE must request [****], within [****]. Failure to [****]. LLNS may [****]. 

  

	12.3	All costs of preparing, filing, prosecuting, and maintaining foreign patent applications and patents covering the [****]. The costs of any interferences and oppositions for foreign patents will be considered prosecution
expenses and [****]. LLNS shall [****]. 

  

	12.4	The preparation, filing, and prosecution of foreign patent applications, as well as the maintenance of the resulting patents, shall be [****]. LLNS shall [****]. If such [****], such [****]. 

 

	12.5	LICENSEE may [****]. LICENSEE is responsible for [****]. 

  

	12.6	LICENSEE will notify LLNS of any change of its status as a small entity (as defined by the United States Patent and Trademark Office) and of the first sublicense granted to an entity that does not qualify as a
small entity. 

  

	13.	PATENT INFRINGEMENT 

  

	13.1	In the event that LLNS (to the extent of the actual knowledge of the licensing professional responsible for the administration of this Agreement) or LICENSEE learns of infringement of potential commercial
significance of any patent licensed under this Agreement, the knowledgeable party will [****]. During the period in which, and in the jurisdiction where, [****]. 

  

	13.2	If infringing activity of potential commercial significance by the infringer has [****]. 

  

	13.3	If, within a [****]. 

  

	13.4	Any recovery or settlement received in connection with any suit and directly attributable to the Licensed Patents will [****]. 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 21 

	13.5	[****]. 

  

	13.6	Each party will cooperate with the other in litigation proceedings instituted hereunder but [****]. 

  

	13.7	[****]. 

  

	14.	USE OF NAMES AND TRADEMARKS 

 Nothing contained in this Agreement will be construed as
conferring any right to either Party to use in advertising, publicity, or other promotional activities any name, trade name, trademark, or other designation of the other Party (including a contraction, abbreviation or simulation of any of the
foregoing). Unless consented to in writing by LLNS, the use by LICENSEE of the name “Lawrence Livermore National Laboratory” or “Lawrence Livermore National Security, LLC” in advertising, publicity, or other promotional
activities is expressly prohibited. 
  

	15.	LIMITED WARRANTY 

  

	15.1	LLNS warrants to LICENSEE that it has the lawful right to grant this license. 

  

	15.2	Except as expressly set forth in this Agreement, the licenses and the associated Invention, Patent Rights, Licensed Products, Licensed Services, and Licensed Methods are provided by LLNS WITHOUT WARRANTY OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED. LLNS MAKES NO EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY THAT THE INVENTION, PATENT RIGHTS, LICENSED PRODUCTS, OR LICENSED METHODS
WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK OR OTHER RIGHTS. 

  

	15.3	Nothing in this Agreement is or will be construed as: 

  

	 	15.3.1	a warranty or representation by LLNS as to the validity, enforceability, or scope of any Patent Rights; or 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 22 

	 	15.3.2	a warranty or representation that anything made, used, sold, or otherwise disposed of under any license granted in this Agreement is or will be free from infringement of patents, copyrights, or other rights of third
parties; or 

  

	 	15.3.3	an obligation to bring or prosecute actions or suits against third parties for patent infringement except as provided in Article 13 (PATENT INFRINGEMENT); or 

 

	 	15.3.4	conferring by implication, estoppel, or otherwise any license or rights under any patents or other rights of LLNS other than Patent Rights, regardless of whether such patents are dominant or subordinate to Patent
Rights; or 

  

	 	15.3.5	an obligation to furnish any New Developments, know-how, technology, or technological information not provided in Patent Rights. 

  

	15.4	LIMITATION OF LIABILITY—LLNS OR DOE WILL NOT BE LIABLE FOR ANY LOST PROFITS, COSTS OF PROCURING SUBSTITUTE GOODS OR SERVICES, LOST BUSINESS, ENHANCED DAMAGES FOR INTELLECTUAL PROPERTY INFRINGEMENT, OR FOR ANY
INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, OR OTHER SPECIAL DAMAGES SUFFERED BY LICENSEE, SUBLICENSEES, JOINT VENTURES, OR AFFILIATES ARISING OUT OF OR RELATED TO THIS AGREEMENT, FOR ALL CAUSES OF ACTION OF ANY KIND (INCLUDING TORT,
CONTRACT, NEGLIGENCE, STRICT LIABILITY AND BREACH OF WARRANTY) EVEN IF LLNS HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 

  

	16.	INDEMNIFICATION 

  

	16.1	[****]. 

  

	16.2	LLNS will, as a condition of LICENSEE’s obligations above (i) provide to LICENSEE prompt notice of any third party claim or demand that may be the subject of Paragraph 16.1; (ii) [****].
LICENSEE shall keep LLNS informed on a current basis of its defense of any claims under this Article 16. 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 23 

	17.	INSURANCE 

  

	17.1	LICENSEE will insure its activities relating to this Agreement at its own cost with an insurance company acceptable to LLNS. LICENSEE will obtain, keep in force, and maintain insurance as follows with an
insurance company acceptable to LLNS or an equivalent program of self-insurance: Comprehensive or Commercial Form General Liability Insurance, including contractual liability and product liability, with coverage as follows: 

 

	 	17.1.1	Each occurrence coverage of not less than [****] and 

  

	 	17.1.2	Product Liability Insurance: Completed operations aggregate coverage of not less than [****]; and 

  

	 	17.1.3	Personal and Advertising Injury: Coverage of not less than [****] and 

  

	 	17.1.4	General Aggregate (Commercial Form only): Coverage of not less than [****]. 

  

	17.2	These coverages do not limit the liability of LICENSEE to LLNS in any way. LICENSEE will provide LLNS, upon request, with certificates of insurance or self-insurance, including renewals that show
compliance with these requirements. LICENSEE’s failure to maintain such required insurance will be considered a material breach of this Agreement. 

  

	17.3	If the required insurance is written on a claims-made form, coverage must provide a retroactive date of placement before or coinciding with the Effective Date of this Agreement. 

 

	17.4	LICENSEE will maintain the general liability insurance specified in this Article 17 during the period that the Licensed Patents of LLNS are being used and/or Licensed Products are being sold or otherwise
commercially distributed by LICENSEE, and for a period of not less than three (3) years thereafter. 

  

	17.5	LICENSEE’S insurance coverage must: 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 24 

	 	17.5.1	Provide for at least thirty (30) days advance written notice to LLNS of cancellation or any modification; and 

  

	 	17.5.2	Indicate that DOE, LLNS, and their respective officers, employees, students, and agents, are endorsed on the policy as additional insureds; and 

 

	 	17.5.3	Include a provision that the coverage is primary and does not participate with or is in excess of any valid and collectible insurance, program, or self-insurance carried or maintained by LLNS. 

 

	18.	WAIVER 

  

	18.1	No provision of this Agreement is deemed waived and no breach excused unless such waiver or consent is made in writing and signed by the waiving or consenting Party. 

 

	18.2	Failure on the part of either Party to exercise or enforce any right of such Party under this Agreement will not be a waiver by such Party of any right, or operate to bar the enforcement or exercise of the right at any
time thereafter. 

  

	19.	ASSIGNABILITY 

 This Agreement may be assigned by LLNS, [****]. 

 

	20.	LATE PAYMENTS 

 In the event that royalty payments, fees, or other monies owed to LLNS
are not received by LLNS when due, LICENSEE will pay to LLNS interest at a rate of [****] simple interest per annum. Such interest will be calculated from the date payment was due until actually received by LLNS. Such accrual of interest will
be in addition to, and not in lieu of, enforcement of any other rights of LLNS due to such late payment. LICENSEE will pay any costs incurred by LLNS in collecting late payments. 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 25 

	21.	NOTICES 

  

	21.1	Any notice or payment required to be given to either Party will be deemed to have been properly given and to be effective: 

  

	 	21.1.1	on the date of delivery if delivered in person; or 

  

	 	21.1.2	on the date of mailing if mailed by first-class certified mail, postage paid; or 

  

	 	21.1.3	on the date of mailing if mailed by any global express carrier service that requires the recipient to sign the documents demonstrating the delivery of such notice of payment; 

to the respective addresses given below, or to another address as designated in writing by the Party changing its address. 

 

			
	    In the case of LICENSEE:	  	 RainDance Technologies, Inc.
 44 Hartwell
Ave
 Lexington MA 02421
 Phone: (781) 861-6300

Fax: (781) 861-1233
 Attention: President

		
	    In the case of LICENSEE:	  	RainDance Technologies, Inc.
		  	44 Hartwell Ave
		  	Lexington MA 02421
		  	Phone: (781)861-6300
		  	Fax: (781)861-1233
		  	Attention: Contract Administrator
		
	    In the case of LLNS:	  	
		
	    All correspondence, original progress reports, and royalty reports:	  	Lawrence Livermore National Laboratory
		  	Industrial Partnerships Office
		  	P.O. Box 808, L-795
		  	7000 East Avenue, L-795
		  	Livermore, CA 94550
		  	Attention: Director, Industrial Partnerships
		  	Fax: (925) 423-8988

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 26 

			
	    Payments and copies of corresponding royalty reports:	  	Lawrence Livermore National Laboratory
		  	P.O. Box 5517
		  	Livermore, CA 94551

  

	22.	GOVERNING LAWS; VENUE; ATTORNEYS FEES 

  

	22.1	The Parties will attempt to jointly and promptly resolve any disputes arising from this Agreement. If the Parties are unable to resolve a dispute within a reasonable time from one Party’s written notice to the
other that dispute resolution has begun, then either Party may commence proceedings in a court of competent jurisdiction. 

  

	22.2	THIS AGREEMENT WILL BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA, excluding any choice of law rules that would direct the application of the laws of another jurisdiction, but the
scope and validity of any patent or patent application will be governed by the applicable laws of the country of such patent or patent application. Any legal action related to this Agreement will be conducted in the State of California.

  

	23.	PATENT MARKING 

 LICENSEE will mark all Licensed Products and their containers
that are made, used, Sold, or otherwise disposed of under this Agreement in accordance with applicable patent marking laws. 
  

	24.	GOVERNMENT APPROVAL OR REGISTRATION 

 If this Agreement or any associated transaction is
required by the law of any nation to be either approved, permitted, or registered with any governmental agency, LICENSEE will assume all legal obligations to do so. LICENSEE will notify LLNS if LICENSEE becomes aware that this
Agreement is subject to a United States or foreign government reporting, permitting, or approval requirement. LICENSEE will make all necessary filings and pay all costs including fees, penalties, and all other out-of-pocket costs associated
with such reporting, permitting, or approval process. 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 27 

	25.	COMPLIANCE WITH LAWS 

  

	25.1	LICENSEE will comply with all applicable international, national, state, regional and local laws and regulations in performing its obligations hereunder and in its use, manufacture, Sale, or import of the
Licensed Products, Licensed Services, or practice of the Licensed Method. 

  

	25.2	LICENSEE will comply with all applicable United States and foreign laws with respect to the transfer of Licensed Products and related technical data and the provision of Licensed Services to foreign countries,
including, without limitation, the International Traffic in Arms Regulations (ITAR) and the Export Administration Regulations (EAR). 

  

	25.3	LICENSEE will manufacture Licensed Products and practice the Licensed Method in compliance with applicable government importation laws and regulations of a particular country for Licensed Products made outside
the particular country in which such Licensed Products are used or Sold. 

  

	26.	FORCE MAJEURE 

  

	26.1	Except for LICENSEE’s obligation to make any payments to LLNS hereunder, the Parties will not be responsible for any failure to perform due to the occurrence of any events beyond their reasonable control
which render their performance impossible or onerous, including, but not limited to: accidents (environmental, toxic spill, etc.); acts of God; biological or nuclear incidents; casualties; earthquakes; fires; floods; governmental acts, orders or
restrictions; inability to obtain suitable and sufficient labor, transportation, fuel and materials; local, national, or state emergency; power failure and power outages; acts of terrorism; strike; and war. 

 

	26.2	Either Party to this Agreement, however, will have the right to terminate this Agreement upon thirty (30) days prior written notice if either Party is unable to fulfill its obligations under this Agreement due to
any of the causes mentioned in Paragraph 26.1 for a period of one (1) year. 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 28 

	27.	[****] 

 [****]. 

 

	28.	MISCELLANEOUS 

  

	28.1	The headings of the several sections are inserted for convenience of reference only and are not intended to affect the meaning or interpretation of this Agreement. 

 

	28.2	No amendment or modification of this Agreement will be valid or binding upon the Parties unless made in writing and signed on behalf of each Party. 

 

	28.3	This Agreement with the attached Exhibits A, B, C, and D embodies the entire understanding of the Parties and supersedes all previous communications, representations, or understandings, whether oral or written, between
the Parties relating to the subject matter hereof. 

  

	28.4	If any of the provisions contained in this Agreement are held to be invalid, illegal, or unenforceable in any respect, such invalidity, illegality, or unenforceability will not affect any other provisions hereof, and
this Agreement will be construed as if such invalid or illegal or unenforceable provisions had never been contained herein. 

  

	28.5	No provisions of this Agreement are intended or will be construed to confer upon or give to any person or entity other than LLNS and LICENSEE any rights, remedies, or other benefits under, or by reason of, this
Agreement. 

  

	28.6	In performing their respective duties under this Agreement, each of the Parties will be operating as an independent contractor. Nothing contained herein will in any way constitute any association, partnership, or joint
venture between the Parties hereto, or be construed to evidence the intention of the Parties to establish any such relationship. Neither Party will have the power to bind the other Party or incur obligations on the other Party’s behalf without
the other Party’s prior written consent. 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 29 

 In witness whereof, both LLNS and LICENSEE have executed this Agreement, in duplicate originals, by their
respective officers hereunto duly authorized, on the date and year hereinafter written. 
  

							
		 	RAINDANCE TECHNOLOGIES, INC	 	LAWRENCE LIVERMORE
		 		 	NATIONAL LABORATORY
		 		 	LAWRENCE LIVERMORE
		 		 	NATIONAL LABORATORY
				
	By:	 	 /s/ Christopher McNary
	 	By:	 	 /s/ George H. Miller

		 	(Signature)	 		 	(Signature)
	Name:	 	 Christopher McNary
	 	Name:	 	George H. Miller
	Title:	 	President and CEO	 	Title:	 	Director, LLNL
	Date signed: Sept. 8, 2008	 	Date signed: 18 Sept., 2008

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 30 

 EXHIBIT A—LICENSED PATENTS 

The Licensed Patents are as follows: 
  

	[****]	

 [****] 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 31 

 EXHIBIT B—RIGHTS GRANTED AND PERFORMANCE OBLIGATIONS 

NOTICE 
 LICENSEE
considers information in this Exhibit B to be Proprietary. 
  

	B.1	Rights Granted 

 Subject to the limitations set forth in this Agreement, LLNS hereby
grants to LICENSEE a [****], license under Patent Rights to [****]. 
 “Field of Use” means [****]. 

 

	B.2	Sublicensing Rights 

  

	B.2.1	LLNS also grants to LICENSEE, so long as it [****]. 

  

	B.2.2	Notwithstanding anything to the contrary in Subparagraph B.2.1 or anywhere else in the Agreement, LICENSEE may [****]. 

  

	B.3	Rights Excluded 

 Rights that are not specifically granted elsewhere in this Agreement
are specifically excluded from the License. 
  

	B.4	[****] 

 [****]. 

 

	B.5	Performance Obligations 

  

	B.5.1	LICENSEE will [****]. 

  

	B.5.2	The sales requirements specified above may, by mutual written consent of LICENSEE and LLNS, be amended and/or extended at the written request of LICENSEE to LLNS, based upon legitimate business reasons
specified in reasonable detail in such written request. 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 32 

	B.5.3	The first progress report will be due on [****]. 

  

	B.5.4	LICENSEE will use Diligent Efforts to develop, file relevant regulatory applications for and attempt to obtain relevant regulatory commercialization approvals with respect to the manufacturing, marketing, and
sale of Licensed Products. 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 33 

 EXHIBIT C—FEES AND ROYALTIES 

NOTICE 
  

	LICENSEE 	considers information in this Exhibit C to be Proprietary. 

  

	C.1	License Issue Fee 

  

	C.1.1	As partial consideration for this Agreement, LICENSEE will pay to LLNS a nonrefundable issue fee of [****] (the “License Issue Fee”), of which [****] will be credited to the LICENSEE for [****].
The License Issue Fee is to be paid [****] as follows: 

  

	 	C.1.1.1	[****] when [****], and 

  

	 	C.1.1.2	[****] due on [****]. 

  

	C.1.2	LLNS will execute the Agreement after [****]. 

  

	C.1.3	The License Issue Fee [****]. 

  

	C.1.4	In the event that LICENSEE grants sublicenses, LICENSEE will pay to LLNS an amount equal to the greater of (i) [****] or (ii) [****] (v) [****] (x) [****] (y) [****] and
(z) [****]. 

  

	C.2	Earned Royalties 

  

	C.2.1	In addition to the License Issue Fee, LICENSEE will pay LLNS an earned royalty of (i) [****] on Net Sales of Licensed Products, and (ii) [****] on the Net Sales of Licensed Services. Payments of earned
royalties will be in accordance with the requirements of Article 5 (FEES, ROYALTIES AND PAYMENTS) and Article 7 (PROGRESS AND ROYALTY REPORTS) of this Agreement. 

  

	C.2.2	In the event that LICENSEE grants a sublicense to a sublicensee, LICENSEE will pay LLNS an earned royalty of (i) [****] and (ii) [****] in accordance with the [****]. 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 34 

	C.3	Minimum Annual Royalties 

  

	C.3.1	LICENSEE will pay to LLNS a minimum annual royalty according to the requirements of Article 5 and the schedule below. The minimum annual royalty paid to LLNS during a calendar year will be credited against the
earned royalty due and owing for the calendar year in which the minimum payment was made. 

  

					
	 Calendar year
	  	 Minimum annual royalty
	  	Due date
	[****]	  	[****]	  	[****]
	[****]	  	[****]	  	[****]
	[****]	  	[****]	  	[****]
	[****]	  	[****]	  	[****]
	[****]	  	[****]	  	[****]
	[****]	  	[****]	  	[****]
	[****]	  	[****]	  	[****]

  

	C.3.2	LICENSEE will pay to LLNS [****]. 

  

	C.4	Assignment Fee 

 LICENSEE will pay LLNS an Assignment Fee of [****] prior to the
granting of such assignment in accordance with Article 19 (ASSIGNABILITY). 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 35 

 EXHIBIT D—MUTUAL NONDISCLOSURE AGREEMENT 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 36 

 MUTUAL NONDISCLOSURE AGREEMENT FOR EXCHANGE OF INFORMATION WITH LAWRENCE LIVERMORE NATIONAL
LABORATORY 
 This Agreement, effective on the date the last party signs, is made by and between RAINDANCE TECHNOLOGIES located at 530 Whitfield Street,
Guilford, Connecticut 06437, and LAWRENCE LIVERMORE NATIONAL SECURITY, LLC, (LLNS), under its Contract No. DE-AC52-07NA27344 with the U.S. DEPARTMENT OF ENERGY (“DOE”), as operators of the LAWRENCE LIVERMORE NATIONAL LABORATORY
(“LLNL”), located at 7000 East Avenue, Livermore, CA 94550. 
 WHEREAS, LLNS, as operators of LLNL, and RAINDANCE TECHNOLOGIES (hereinafter
individually referred to as the “PARTY” or collectively as the “PARTIES”) wish to exchange certain confidential and proprietary information relating to LLNL’s licensing and market research data and RAINDANCE
TECHNOLOGIES’ business plans, sales and marketing research, and financial data (“PROPRIETARY INFORMATION”), this Agreement will govern the conditions of mutual disclosure of PROPRIETARY INFORMATION by the PARTIES. 

The PARTIES hereby agree: 
  

	 	(1)	To perform all terms of this Agreement and to maintain the PROPRIETARY INFORMATION in confidence, giving it the same degree of care, but no less than a reasonable degree of care, as the receiving PARTY exercises with
its own proprietary information to prevent its unauthorized disclosure. 

  

	 	(2)	To exchange and use the PROPRIETARY INFORMATION solely for the purpose of evaluation, testing, and development of potential collaborations, joint ventures, and/or license of the technology. 

 

	 	(3)	That neither PARTY, without the prior written consent of the other, will disclose any portion of the PROPRIETARY INFORMATION to others except to their employees, agents, consultants, subcontractors or Government
personnel having a need to know in order to accomplish the sole purpose stated above, and who are bound by a like obligation of confidentiality under this Agreement. 

 

	 	(4)	That neither PARTY will have any obligation, nor will the DOE, assume any liability with respect to any portion of the PROPRIETARY INFORMATION that: 

 

	 	(a)	the receiving PARTIES can demonstrate by written record was previously known to them; 

  

	 	(b)	is, or becomes, available to the public through no fault of the PARTIES; 

  

	 	(c)	is lawfully obtained by the PARTIES from a third party and is not subject to an obligation of confidentiality owed to the third party; or 

 

	 	(d)	is independently developed by or for the PARTIES independent of any disclosure hereunder. 

  

	 	(5)	That PROPRIETARY INFORMATION disclosed by the PARTIES will be in writing and clearly marked “PROPRIETARY INFORMATION” or its equivalent. If such PROPRIETARY INFORMATION is initially disclosed orally or by
demonstration, it will be identified as PROPRIETARY INFORMATION or its equivalent at the time of disclosure. The disclosing PARTY will, within thirty (30) days thereafter: (a) reduce such PROPRIETARY INFORMATION to writing or other
tangible form, referencing the date and type of PROPRIETARY INFORMATION disclosed, and mark it as PROPRIETARY INFORMATION or its equivalent; and (b) deliver a copy to the receiving PARTY. All protections and restrictions as to use and
disclosure will apply during such thirty (30) day period. 

  

	 	(6)	That all rights and title to the PROPRIETARY INFORMATION disclosed under this Agreement will remain the property of disclosing PARTY unless otherwise agreed to in writing by the PARTIES. 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 37 

	 	(7)	That PROPRIETARY INFORMATION provided by any disclosing PARTY to any receiving PARTY shall be returned to the disclosing PARTY within five (5) days of written request for such return by the disclosing PARTY.

  

	 	(8)	That no copies shall be made by a receiving PARTY of any PROPRIETARY INFORMATION without the express written consent of the disclosing PARTY. Any copies so authorized shall be returned to the disclosing PARTY or
destroyed in accordance with the term and demand provisions of this Agreement. 

  

	 	(9)	That the receiving PARTY agrees that with regard to any patent application provided as PROPRIETARY INFORMATION under this Agreement that no protest, public use proceeding, copied claims for provoking interference, or
other action impeding issuance of any patent based on the disclosed application shall be filed by the receiving PARTY prior to the publication of such patent application. 

 

	 	(10)	The PARTIES agree that any photocopy or facsimile copy of this fully-executed Agreement shall have the same legal force and effect as any copy bearing original signatures of the PARTIES. 

 

							
	Contact for Company:	  	Contact for LLNL:
				
	Name:	  	Robert Cunningham	  	Name:	  	Catherine Elizondo
	Company:	  	RainDance Technologies	  	Company:	  	Lawrence Livermore National Laboratory
	Address:	  	530 Whitfield Street	  	Address:	  	7000 East Avenue
		  	Guilford, CT 06437	  		  	L-795
		  		  		  	Livermore, CA 94550
	Phone:	  	203 458 2947	  	Phone:	  	925 422 0801
	Fax:	  	203 458 2514	  	Fax:	  	925 423 8988
	Email:	  	cunninghamr@raindancetechnologies.com	  	Email:	  	Elizondo1@LLNL.gov

 It is further agreed that the furnishing of PROPRIETARY INFORMATION does not constitute any grant or license to the other
PARTY for any legal rights now or hereinafter held by either PARTY. 
 This Agreement will be subject to, and interpreted in accordance with, the laws of
the State of California. 
 Unless terminated earlier by thirty (30) days written notice by either PARTY to the other, this Agreement will remain in
effect for two, (2) year(s) from the effective date, at which time the receiving PARTY will return or destroy the PROPRIETARY INFORMATION within thirty (30) days of the termination of this Agreement. If the
PROPRIETARY INFORMATION is destroyed, a certificate of destruction must be furnished to the disclosing PARTY within the thirty (30) days. The secrecy and non-use obligations of the receiving PARTY set forth above will remain in effect for five
(5) years from the effective date. 
 The receiving PARTY acknowledges its obligations to control access to technical data under the U.S. Export Laws
and Regulations and agrees to adhere to such Laws and Regulations with regard to any technical data received under this Agreement. 
 Any modification to
this Agreement must be in writing and signed by the duly authorized representative of each PARTY. 
 LAWRENCE LIVERMORE NATIONAL SECURITY, LLC, 

LAWRENCE LIVERMORE NATIONAL LABORATORY 
 Signature: /s/ Kathy
Kaufman 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 38 

	
	 Signing for: Erik Stenehjem
 Title:
  Director, Industrial Partnerships Office

	
	  
 Date:  2/26/08

 

	
	 RAINDANCE TECHNOLOGIES
  

	
	Signature  /s/ Robert W. Cunningham                    
	
	Type Name: Robert W. Cunningham
	
	Title: Vice President, Business Development
	
	Date:  2/26/08
	
	  
 RETURN TO: Lawrence Livermore

                        National
Laboratory

                        ATTN: Terry
Contreras L-795

                        7000 East
Avenue

                        Livermore, CA
94550
  

cc:         Catherine Elizondo L-795

IPO                   

 10/1/2007

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 39 

 AMENDMENT TO NONDISCLOSURE AGREEMENT 

AMENDMENT NUMBER 1 
 This amends the
Mutual Nondisclosure Agreement, dated February 26, 2008, between RainDance Technologies and Lawrence Livermore National Security, LLC, Lawrence Livermore National Laboratory. 

The proprietary information in the February 26, 2008, Agreement is: “LLNL’s licensing and market research data and RainDance Technologies’
business plans, sales and marketing research, and Financial data.” 
 The parties agree that the Mutual Nondisclosure Agreement should be amended to
expand the proprietary information for LLNL to include: [****] 
 All other terms and conditions in the Agreement shall remain the same. Attached is a copy
of the Mutual Nondisclosure Agreement. Please indicate your acceptance to the above-identified changes by signing this amendment. , 
  

	
	RAINDANCE TECHNOLOGIES
	
	  
 Signature  /s/ Robert W.
Cunningham                                    

	
	 Name: Robert W. Cunningham
 Title:
  Vice President, Business Development

	
	Date:  4-17-08
	
	  
 LAWRENCE LIVERMORE NATIONAL SECURITY, LLC,

LAWRENCE LIVERMORE NATIONAL LABORATORY

	
	  
 Signature:  /s/ Erik
Stenehjem                                        
        

	
	 Name: Erik Stenehjem
 Title:
  Director, Industrial Partnerships Office

	
	  
 Date:  4-17-08

	
	  
 RETURNTO: Lawrence Livermore
National Laboratory

                   
     ATTN:Terry Confreres L-795

                        7000 East
Avenue

                        Livermore, CA
94550
  

cc:         Catherine Elizondo L-795

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 40 

 AMENDMENT TO NONDISCLOSURE AGREEMENT 

AMENDMENT NUMBER 2 
 This amends the
Mutual Nondisclosure Agreement, dated February 26, 2008, between RainDance Technologies and Lawrence Livermore National Security, LLC, Lawrence Livermore National Laboratory. 

The parties agree that the Mutual Nondisclosure Agreement should be amended to expand the proprietary information for LLNL to include “information
relating to [****]. 
 All other terms and conditions in the Agreement shall remain the same. Attached is a copy of the Mutual Nondisclosure Agreement
Please indicate your acceptance to the above-identified changes by signing this amendment. 
  

	
	RAINDANCE TECHNOLOGIES
	
	  
 Signature  /s/ Robert W.
Cunningham                                    

	
	 Name: Robert W. Cunningham
 Title:
  Vice President, Business Development

	
	  
 Date:  4/29/08

	
	  
 LAWRENCE LIVERMORE NATIONAL SECURITY, LLC,

LAWRENCE LIVERMORE NATIONAL LABORATORY
  

	
	Signature:  /s/ Nina
Potter                                        

	
	 Signing for: Erik Stenehjem
 Title:
  Director, Industrial Partnerships Office

	
	  
 Date:  4/29/08

	
	  
 RETURN TO: Lawrence Livermore National Laboratory
                        ATTN: Terry Confreres L-795

                        7000 East
Avenue

                        Livermore, CA
94550
  

cc:         Catherine Elizondo L-795

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

  
 41 

 SUPPLEMENT ONE 

To 
 COEXCLUSIVE 

PATENT LICENSE AGREEMENT 

For 
 NUCLEIC ACID
DETECTION AND ANALYSIS 
 For 

All Fields of Use 

Between 
 LAWRENCE
LIVERMORE NATIONAL SECURITY, LLC 
 and 

RAINDANCE TECHNOLOGIES, INC. 

LLNL Case No. TL02294-0.0 

Lawrence Livermore National Laboratory 

P.O. Box 808, L-795, Livermore, CA 94551 

Industrial Partnerships Office 

September 2, 2009 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 SUPPLEMENT ONE 

September 2, 2009 
 to 

License Agreement—LLNL Case Number TL02294-0.0 

For NUCLEIC ACID DETECTION AND ANALYSIS 

between RainDance Technologies, Inc. and 

Lawrence Livermore National Security, LLC 

effective September 12, 2008 
 This
Supplement One to the License Agreement by and between Lawrence Livermore National Security, LLC (“LLNS”) and RainDance Technologies, Inc. (“LICENSEE”) will be effective as of September 2, 2009. This Supplement and the
associated License Agreement are subject to overriding obligations to the Federal Government pursuant to the provisions of LLNS’s Contract No. DE-AC52-07NA27344 with the United States Department of Energy (“DOE”) for the operation of
the Lawrence Livermore National Laboratory (“LLNL”). 
 This Supplement One will [****]. All other terms and conditions remain the same. This
Supplement One is intended to replace Exhibit A of the License Agreement in its entirety. 
 [****Intentionally Left Blank****] 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXHIBIT A—LICENSED PATENTS 

The Licensed Patents are as follows: 
 [****] 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 SUPPLEMENT TWO 

To 
 COEXCLUSIVE 

PATENT LICENSE AGREEMENT 

For 
 NUCLEIC ACID
DETECTION AND ANALYSIS 
 For 

All Fields of Use 

Between 
 LAWRENCE
LIVERMORE NATIONAL SECURITY, LLC 
 and 

RAINDANCE TECHNOLOGIES, INC. 

LLNL Case No. TL02294-0.0 

Lawrence Livermore National Laboratory 

P.O. Box 808, L-795, Livermore, CA 94551 

Industrial Partnerships Office 

May 14, 2012 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 SUPPLEMENT TWO 

May 14, 2012 
 to 

License Agreement – LLNL Case Number TL02294-0.0 

For NUCLEIC ACID DETECTION AND ANALYSIS 

between RainDance Technologies, Inc. and 

Lawrence Livermore National Security, LLC 

effective September 12, 2008 
 This
Supplement Two to the License Agreement by and between Lawrence Livermore National Security, LLC (“LLNS”) and RainDance Technologies, Inc. (“LICENSEE”) will be effective as of May 14, 2012. This Supplement and the associated
License Agreement are subject to overriding obligations to the Federal Government pursuant to the provisions of LLNS’s Contract No. DE-AC52-07NA27344 with the United States Department of Energy (“DOE”) for the operation of the
Lawrence Livermore National Laboratory (“LLNL”). 
 This Supplement Two will [****]. All other terms and conditions remain the same. This
Supplement Two is intended to replace Exhibit A of the License Agreement in its entirety. 
 [****Intentionally Left Blank****] 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXHIBIT A—LICENSED PATENTS 

The Licensed Patents are as follows: 
 [****] 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 SUPPLEMENT THREE 

To 
 COEXCLUSIVE 

PATENT LICENSE AGREEMENT 

For 
 NUCLEIC ACID
DETECTION AND ANALYSIS 
 For 

All Fields of Use 

Between 
 LAWRENCE
LIVERMORE NATIONAL SECURITY, LLC 
 and 

RAINDANCE TECHNOLOGIES, INC. 

LLNL Case No. TL02294-0.0 

Lawrence Livermore National Laboratory 

P.O. Box 808, L-795, Livermore, CA 94551 

Industrial Partnerships Office 

June 26, 2013 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 SUPPLEMENT THREE 

June 26, 2013 
 to 

License Agreement—LLNL Case Number TL02294-0.0 

For NUCLEIC ACID DETECTION AND ANALYSIS 

between RainDance Technologies, Inc. and 

Lawrence Livermore National Security, LLC 

effective September 18, 2008 
 This
Supplement Three to the License Agreement by and between Lawrence Livermore National Security, LLC (“LLNS”) and RainDance Technologies, Inc. (“LICENSEE”) will be effective as of June 26, 2013. This Supplement and the
associated License Agreement are subject to overriding obligations to the Federal Government pursuant to the provisions of LLNS’s Contract No. DE-AC52-07NA27344 with the United States Department of Energy (“DOE”) for the operation of
the Lawrence Livermore National Laboratory (“LLNL”). 
 This Supplement Three will [****]. All other terms and conditions remain the same. This
Supplement Three is intended to replace Exhibit A of the License Agreement in its entirety. 
 [****Intentionally Left Blank****] 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXHIBIT A—LICENSED PATENTS 

The Licensed Patents are as follows: 
 [****] 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 SUPPLEMENT FOUR 

To 
 COEXCLUSIVE 

PATENT LICENSE AGREEMENT 

For 
 NUCLEIC ACID
DETECTION AND ANALYSIS 
 For 

All Fields of Use 

Between 
 LAWRENCE
LIVERMORE NATIONAL SECURITY, LLC 
 and 

RAINDANCE TECHNOLOGIES, INC. 

LLNL Case No. TL02294-0.0 

Lawrence Livermore National Laboratory 

P.O. Box 808, L-795, Livermore, CA 94551 

Industrial Partnerships Office 

March 17, 2014 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 SUPPLEMENT FOUR 

March 17, 2014 
 to 

License Agreement—LLNL Case Number TL02294-0.0 

For NUCLEIC ACID DETECTION AND ANALYSIS 

between RainDance Technologies, Inc. and 

Lawrence Livermore National Security, LLC 

effective September 18, 2008 
 This
Supplement Four to the License Agreement by and between Lawrence Livermore National Security, LLC (“LLNS”) and RainDance Technologies, Inc. (“LICENSEE”) will be effective as of March 17, 2014. This Supplement and the
associated License Agreement are subject to overriding obligations to the Federal Government pursuant to the provisions of LLNS’s Contract No. DE-AC52-07NA27344 with the United States Department of Energy (“DOE”) for the operation of
the Lawrence Livermore National Laboratory (“LLNL”). 
 This Supplement Four will [****]. All other terms and conditions remain the same. This
Supplement Four is intended to replace Exhibit A of the License Agreement in its entirety. 
 [****Intentionally Left Blank****] 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXHIBIT A—LICENSED PATENTS 

[****] 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 SUPPLEMENT FIVE 

To 
 COEXCLUSIVE 

PATENT LICENSE AGREEMENT 

For 
 NUCLEIC ACID
DETECTION AND ANALYSIS 
 For 

All Fields of Use 

Between 
 LAWRENCE
LIVERMORE NATIONAL SECURITY, LLC 
 and 

RAINDANCE TECHNOLOGIES, INC. 

LLNL Case No. TL02294-0.0 

Lawrence Livermore National Laboratory 

P.O. Box 808, L-795, Livermore, CA 94551 

Industrial Partnerships Office 

April 15, 2014 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 SUPPLEMENT FIVE 

April 15, 2014 
 to 

License Agreement—LLNL Case Number TL02294-0.0 

For NUCLEIC ACID DETECTION AND ANALYSIS 

between RainDance Technologies, Inc. and 

Lawrence Livermore National Security, LLC 

effective September 18, 2008 
 This
Supplement Five to the License Agreement by and between Lawrence Livermore National Security, LLC (“LLNS”) and RainDance Technologies, Inc. (“LICENSEE”) will be effective as of April 15, 2014. This Supplement and the
associated License Agreement are subject to overriding obligations to the Federal Government pursuant to the provisions of LLNS’s Contract No. DE-AC52-07NA27344 with the United States Department of Energy (“DOE”) for the operation of
the Lawrence Livermore National Laboratory (“LLNL”). 
 This Supplement Five will [****]. All other terms and conditions remain the same. This
Supplement Five is intended to replace Exhibit A of the License Agreement in its entirety. 
 [****Intentionally Left Blank****] 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXHIBIT A—LICENSED PATENTS 

[****] 

  
 CONFIDENTIAL TREATMENT REQUESTED
UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. 
 [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED
SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}]]